<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucl Recept Signal</journal-id><journal-id journal-id-type="iso-abbrev">Nucl Recept Signal</journal-id><journal-id journal-id-type="publisher-id">NRS</journal-id><journal-title-group><journal-title>Nuclear Receptor Signaling</journal-title></journal-title-group><issn pub-type="epub">1550-7629</issn><publisher><publisher-name>Nuclear Receptor Signaling Atlas</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4978380</article-id><article-id pub-id-type="publisher-id">nrs14002</article-id><article-id pub-id-type="doi">10.1621/nrs.14002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Estrogen-related receptor &#x003b2; (ERR&#x003b2;) &#x02013; renaissance receptor or receptor renaissance?</article-title><alt-title alt-title-type="left-running">Running Head: A review of ERR&#x003b2; structure and function</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Divekar</surname><given-names>Shailaja D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tiek</surname><given-names>Deanna M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fernandez</surname><given-names>Aileen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Riggins</surname><given-names>Rebecca B.</given-names></name></contrib><aff id="aff1">Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC (SDD, DMT, AF, RBR)</aff></contrib-group><author-notes><corresp id="cor1">Corresponding Author: RBR, <email xlink:href="rbr7@georgetown.edu">rbr7@georgetown.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>21</day><month>6</month><year>2016</year></pub-date><volume>14</volume><elocation-id>e002</elocation-id><history><date date-type="received"><day>05</day><month>11</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016, Divekar et al.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Divekar et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This is an open-access article distributed under the terms of 
the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><abstract><p>Estrogen-related receptors (ERRs) are founding members of the orphan nuclear receptor (ONR) subgroup of the nuclear receptor superfamily. Twenty-seven years of study have yet to identify cognate ligands for the ERRs, though they have firmly placed ERR&#x003b1; and ERR&#x003b3; at the intersection of cellular metabolism and oncogenesis. The pace of discovery for novel functions of ERR&#x003b2;, however, has until recently been somewhat slower than that of its family members. ERR&#x003b2; has also been largely ignored in summaries and perspectives of the ONR literature. Here, we provide an overview of established and emerging knowledge of ERR&#x003b2; in mouse, man, and other species, highlighting unique aspects of ERR&#x003b2; biology that set it apart from the other two estrogen-related receptors, with a focus on the impact of alternative splicing on the structure and function of this receptor.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>ESRRB</kwd><kwd>ERRbeta</kwd><kwd>ERR&#x003b2;</kwd><kwd>NR3B2</kwd><kwd>alternative splicing</kwd><kwd>orphan nuclear receptor</kwd></kwd-group></article-meta><notes><def-list list-type="simple" list-content="abbreviations"><title>Abbreviations: </title><def-item><term>4HT</term><def><p>4-hydroxytamoxifen</p></def></def-item><def-item><term>AIB1</term><def><p>amplified in breast cancer 1</p></def></def-item><def-item><term>AS</term><def><p>alternative splicing</p></def></def-item><def-item><term>BCP ALL</term><def><p>B-cell precursor acute lymphoblastic leukemia</p></def></def-item><def-item><term>BPA</term><def><p>Bisphenol A</p></def></def-item><def-item><term>BLAST</term><def><p>basic local alignment search tool</p></def></def-item><def-item><term>Cdc25A</term><def><p>cell division cycle 25 homolog A</p></def></def-item><def-item><term>cDNA</term><def><p>complementary DNA</p></def></def-item><def-item><term>CDKN1A</term><def><p>cyclin-dependent kinase inhibitor 1A</p></def></def-item><def-item><term>ChIP-seq</term><def><p>chromatin immunoprecipitation and sequencing</p></def></def-item><def-item><term>Crh</term><def><p>corticotrophin releasing hormone</p></def></def-item><def-item><term>Crh2</term><def><p>corticotrophin releasing hormone 2</p></def></def-item><def-item><term>CTE</term><def><p>carboxyl-terminal extension</p></def></def-item><def-item><term>DBD</term><def><p>DNA-binding domain</p></def></def-item><def-item><term>DES</term><def><p>diethylstilbestrol</p></def></def-item><def-item><term>DFNB</term><def><p>nonsyndromic deafness, autosomal recessive</p></def></def-item><def-item><term>dpc</term><def><p>days post coitum</p></def></def-item><def-item><term>Dub3</term><def><p>deubiquitinating enzyme 3</p></def></def-item><def-item><term>EC</term><def><p>embryonal carcinoma</p></def></def-item><def-item><term>ER&#x003b1;</term><def><p>estrogen receptor &#x003b1;</p></def></def-item><def-item><term>ERE</term><def><p>estrogen response element</p></def></def-item><def-item><term>ERRs</term><def><p>estrogen-related receptors</p></def></def-item><def-item><term>ERR&#x003b2;</term><def><p>estrogen-related receptor &#x003b2;</p></def></def-item><def-item><term>ERRE</term><def><p>estrogen-related response element</p></def></def-item><def-item><term>ES</term><def><p>embryonic stem</p></def></def-item><def-item><term>ESC</term><def><p>embryonic stem cell</p></def></def-item><def-item><term>EST</term><def><p>expressed sequence tag</p></def></def-item><def-item><term>FRAP</term><def><p>fluorescence recovery after photobleaching</p></def></def-item><def-item><term>FRET</term><def><p>fluorescence resonance energy transfer</p></def></def-item><def-item><term>FTZ-F1</term><def><p>fushi tarazu factor</p></def></def-item><def-item><term>GBM</term><def><p>glioblastoma</p></def></def-item><def-item><term>GDOC</term><def><p>Georgetown Database of Cancer</p></def></def-item><def-item><term>GEO</term><def><p>gene expression omnibus</p></def></def-item><def-item><term>GR</term><def><p>glucocorticoid receptor</p></def></def-item><def-item><term>GRE</term><def><p>glucocorticoid response element</p></def></def-item><def-item><term>GST</term><def><p>glutathione S-transferase</p></def></def-item><def-item><term>HPA</term><def><p>hypothalamic-pituitary axis</p></def></def-item><def-item><term>IC<sub>50</sub></term><def><p>50% inhibitory concentration</p></def></def-item><def-item><term>iPSC</term><def><p>induced pluripotent stem cell</p></def></def-item><def-item><term>LBD</term><def><p>ligand-binding domain</p></def></def-item><def-item><term>LOH</term><def><p>loss of heterozygosity</p></def></def-item><def-item><term>MPM2</term><def><p>mitotic protein monoclonal #2</p></def></def-item><def-item><term>NCOA3</term><def><p>nuclear receptor coactivator 3</p></def></def-item><def-item><term>NLS</term><def><p>nuclear localization sequence</p></def></def-item><def-item><term>NPY</term><def><p>neuropeptide Y</p></def></def-item><def-item><term>Nrf2</term><def><p>NF-E2 Related Factor 2</p></def></def-item><def-item><term>OMIM</term><def><p>Online Mendelian Inheritance in Man</p></def></def-item><def-item><term>ONRs</term><def><p>orphan nuclear receptors</p></def></def-item><def-item><term>P</term><def><p>postnatal</p></def></def-item><def-item><term>PAX5</term><def><p>paired box 5</p></def></def-item><def-item><term>PGC</term><def><p>primordial germ cells</p></def></def-item><def-item><term>REMBRANDT</term><def><p>Repository for Molecular Brain Neoplasia Data</p></def></def-item><def-item><term>RID</term><def><p>receptor interacting domain</p></def></def-item><def-item><term>RIP140</term><def><p>receptor interacting protein 140</p></def></def-item><def-item><term>SAGE</term><def><p>serial analysis of gene expression</p></def></def-item><def-item><term>Shh</term><def><p>Sonic hedgehog</p></def></def-item><def-item><term>shRNA</term><def><p>small hairpin RNA</p></def></def-item><def-item><term>Smo</term><def><p>Smoothened</p></def></def-item><def-item><term>Sp1</term><def><p>specificity protein 1</p></def></def-item><def-item><term>SRC2</term><def><p>steroid receptor coactivator-2</p></def></def-item><def-item><term>TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item><def-item><term>TR&#x003b1;</term><def><p>thyroid hormone receptor &#x003b1;</p></def></def-item><def-item><term>TREpal</term><def><p>palindromic thyroid hormone response element</p></def></def-item><def-item><term>TSC</term><def><p>trophoblast stem cell</p></def></def-item><def-item><term>UTR</term><def><p>untranslated region</p></def></def-item><def-item><term>YFP</term><def><p>yellow fluorescent protein</p></def></def-item></def-list></notes></front><body><sec sec-type="intro"><title>Introduction</title><sec><title>Gene discovery and orphan designation</title><p>A gene encoding ERR&#x003b2;, initially named hERR2 and subsequently designated NR3B2 or ESRRB, was first reported in 1988 [<xref rid="r34" ref-type="bibr">Gigu&#x000e8;re et al., 1988</xref>]. Gigu&#x000e8;re et al. screened a &#x003bb;gt10 human testis cDNA library with the DNA-binding domain of estrogen receptor &#x003b1; (ER&#x003b1;), isolated a sequence with only partial similarity, then screened that against a human adult heart cDNA library to isolate hERR2 (GenBank ID X51417.1). ERR&#x003b1; (initially designated hERR1) was isolated in parallel from a human fetal kidney cDNA library. The identified hERR2 open reading frame is 433 amino acids in length and contains broad sequence similarity to the DNA-binding domain (DBD) and ligand-binding domain (LBD) of ER&#x003b1;. Northern blot analysis showed that despite widespread expression of hERR1, hERR2 is restricted to a single 4.8 kb transcript in rat heart, kidney, prostate, testis, and tissues of the central nervous system (including the hypothalamus), with human placenta and prostate testing negative for expression [<xref rid="r34" ref-type="bibr">Gigu&#x000e8;re et al., 1988</xref>]. Preliminary steroid binding studies suggested that hERR2 cannot bind androgens or estrogens, making it a founding member of the orphan nuclear receptor (ONR) subgroup.</p><p>Constitutive transcriptional activity of hERR2 was subsequently reported by two groups, who showed that replacement of either the progesterone receptor (PR) or glucocorticoid receptor (GR) LBD with amino acids 173-433 [<xref rid="r57" ref-type="bibr">Lydon et al., 1992</xref>] or 168-433 [<xref rid="r107" ref-type="bibr">Xie et al., 1999</xref>] of hERR2, respectively, drives ligand-independent activation of these chimeric receptors. Xie et al. also showed that intact hERR2 binds to the estrogen response element (ERE) and a palindromic thyroid hormone response element (TREpal), but not the glucocorticoid response element (GRE), and that constitutive activation of hERR2 is enhanced by co-transfection of p160 family coactivator proteins. Like ER&#x003b1; and other nuclear receptors, hERR2 can also indirectly modulate target gene transcription by coopting specificity protein 1 (Sp1) sites, including those in thyroid hormone receptor &#x003b1; (TR&#x003b1;) and cyclin-dependent kinase inhibitor 1A (CDKN1A, p21) [<xref rid="r13" ref-type="bibr">Castet et al., 2006</xref>], and appears to be a more potent activator of Sp1-driven transcription than either ERR&#x003b1; or ERR&#x003b3;. By contrast, hERR2 represses GR-mediated transcriptional activity at GREs without altering the ability of the GR to bind DNA [<xref rid="r88" ref-type="bibr">Trapp and Holsboer, 1996</xref>] and is itself transcriptionally repressed by another ONR, DAX1 [<xref rid="r83" ref-type="bibr">Suzuki et al., 2003</xref>].</p><p>The mouse ortholog, mERR-2 (GenBank ID S82458.1), was cloned from undifferentiated embryonal carcinoma (EC) and embryonic stem (ES) cells [<xref rid="r71" ref-type="bibr">Pettersson et al., 1996</xref>]. A single 4.3 kb transcript (predicted open reading frame = 433 amino acids) is readily detected by Northern blot in undifferentiated murine F9 EC and ES cells, though only weakly expressed in adult mouse kidney and heart tissues, and retinoic acid-induced differentiation of F9s strongly suppresses mERR-2 expression. Functional studies with the mERR-2 cDNA in gel-shift assays show that, like hERR2, this receptor binds to EREs, but not direct repeats bound by retinoid X receptor heterodimers, and that hERR2 homodimerizes in solution and on EREs in a manner requiring functional heat shock protein 90 (hsp90) [<xref rid="r71" ref-type="bibr">Pettersson et al., 1996</xref>]. The murine and human genes were subsequently mapped to chromosomes 12 and 14q24.3, respectively [<xref rid="r81" ref-type="bibr">Sladek et al., 1997</xref>]. Table 1 summarizes the GenBank identifiers for human, mouse, and rat ESRRB.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>GenBank Identifiers for ESRRB</title></caption><table frame="hsides" rules="groups"><col width="32.39%" span="1"/><col width="34.09%" span="1"/><col width="33.52%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Species</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>GenBank Identifier #</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Transcripts</underline></th></tr></thead><tbody><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Human<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">AF094517.1<break/>NM_004452.3<break/>AY451389.1<break/>AY451390.1<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR&#x003b2;2<break/>ERR&#x003b2;<break/>ERR&#x003b2;<break/>ERR&#x003b2;<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Mouse<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">S82458.1<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">mERR-2<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Rat</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">X51417.1*<break/>AY383731.1</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2*<break/>rERR&#x003b2;</td></tr></tbody></table><table-wrap-foot><p>* denotes transcript first identified as human ERR&#x003b2;.</p></table-wrap-foot></table-wrap></sec><sec><title>A model for understanding ONR/DNA interactions</title><p>A distinctive feature of ONRs is the ability of many to bind as monomers to DNA sequences resembling half of the canonical steroid receptor inverted repeats, but with a 5&#x02019; extension (termed extended half-sites, e.g. [<xref rid="r42" ref-type="bibr">Ikeda et al., 1993</xref>; <xref rid="r92" ref-type="bibr">Ueda et al., 1992</xref>]. In the related <italic>Drosophila melanogaster</italic> fushi tarazu factor (FTZ-F1) receptor, this capability had been attributed to a carboxyl-terminal extension (CTE) of the DBD [<xref rid="r92" ref-type="bibr">Ueda et al., 1992</xref>]. Wright and colleagues solved nuclear magnetic resonance (NMR) solution structures of the DBD of hERR2 (amino acids 96-194) in complex with DNA to formally prove that the CTE (amino acids 169-194) is required for hERR2 binding to what is now known as the estrogen-related response element (ERRE, sequence <underline>TCA</underline>AGGTCA), and that this is accomplished through insertion of the T- and A-boxes, also called an AT hook, into the minor groove of DNA (Protein Data Bank ID # 1LO1) [<xref rid="r32" ref-type="bibr">Gearhart et al., 2003</xref>; <xref rid="r77" ref-type="bibr">Sem et al., 1997</xref>]. CTE/DNA minor groove interactions involving the <underline>TCA</underline> sequence are essential for recognition by the hERR2 CTE, since synthetic polyamides (pyrrole-imidazole oligomers) that occlude it prevent DNA binding by hERR2 [<xref rid="r33" ref-type="bibr">Gearhart et al., 2005</xref>]. These detailed studies established hERR2 as a prototypical model for monomeric ONR/DNA interactions. It should be noted, however, that for other ERR family members, DNA binding more commonly occurs in a homodimeric fashion [<xref rid="r84" ref-type="bibr">Takacs et al., 2013</xref>; <xref rid="r96" ref-type="bibr">Vanacker et al., 1999</xref>], with deviance at the cytosine within the AT hook driving a preference for monomeric vs. dimeric binding of ERR&#x003b1; [<xref rid="r5" ref-type="bibr">Barry et al., 2006</xref>].</p></sec></sec><sec><title>Controversy and complexity &#x02013; identifying the real ERR&#x003b2; and its splice variants</title><p>In 1999, Chen et al. published a study that called into question the true species of origin for hERR2, which was by now widely accepted as human ERR&#x003b2; [<xref rid="r15" ref-type="bibr">Chen et al., 1999</xref>]. Using an informatics-centric approach, the authors relied on rapidly expanding expressed sequence tag (EST) databases to identify novel nuclear receptor-like sequences, then adapted inverse PCR-based cloning to identify two ERRs, hERR&#x003b2;2 (GenBank ID AF094517.1, see Table 1) and hERR&#x003b3;2 from human testis and fetal brain cDNA libraries, respectively. Their hERR&#x003b2;2 sequence has several key differences with the original hERR2, despite being cloned from the same tissue and having 90% nucleotide and 95% protein sequence identity between most of their open reading frames. hERR&#x003b2;2 codes for an additional 67 amino acids at the carboxyl terminus, there is no homology between its 5&#x02019; and 3&#x02019; untranslated regions (UTRs) and those of hERR2, and Northern blot analysis with probes designed from its 3&#x02019; UTR identified low but detectable expression of multiple transcripts ranging from 1.0 to 5.5 kb in length in a range of human tissues, including heart, kidney, and liver. The lack of homology between UTRs, coupled with the inability of primers designed against hERR2 to amplify any product from human genomic DNA, demonstrated that hERR&#x003b2;2 and hERR2 are distinct genes and suggested that the latter might not, in fact, be of human origin. Chen et al. went on to show that hERR2 is actually the rat ERR&#x003b2; gene, the full sequence of which (GenBank AY383731.1) would not be deposited for another four years, while hERR&#x003b2;2 is the true human ERR&#x003b2; [<xref rid="r15" ref-type="bibr">Chen et al., 1999</xref>].</p><sec><title>Primate-specific alternative splicing</title><p>Pre-messenger RNA (pre-mRNA) splicing is a process that is carried out by the spliceosome, a massive multi-protein complex that removes introns and joins together exons into a mature mRNA transcript [<xref rid="r109" ref-type="bibr">Yan et al., 2015</xref>]. Alternative splicing (AS) allows a single gene to combine its exons into multiple configurations, and has become the accepted theory as to how eukaryotic cells are able to translate 90,000 proteins from only 25,000 genes [<xref rid="r75" ref-type="bibr">Roy et al., 2013</xref>]. The multiple hERR&#x003b2;2 transcripts identified in [<xref rid="r15" ref-type="bibr">Chen et al., 1999</xref>] imply the existence of AS and/or multiple transcriptional start/stop sites for human ERR&#x003b2;. Consistent with this, their PCR-based validation studies with primers designed towards the amino terminus of hERR&#x003b2;2 could only detect expression in testis (the tissue from which it was cloned), while hERR&#x003b2;2 carboxyl terminal primers amplified product in human heart, kidney, and liver, where Northern blot studies show expression.</p><p>The existence of ERR&#x003b2; AS was formally demonstrated in 2006, when Zhou et al. showed that there are at least three distinct human ERR&#x003b2; variants: the previously identified hERR&#x003b2;2 and two new forms, ERR&#x003b2;&#x02206;10 (&#x02206;10) and &#x02018;short form&#x02019; ERR&#x003b2; (ERR&#x003b2;sf, <xref ref-type="fig" rid="f1">Figure 1A</xref>) [<xref rid="r114" ref-type="bibr">Zhou et al., 2006</xref>]. At the mRNA level, ERR&#x003b2;2 includes 12 exons, &#x02206;10 is comprised of exons 3-9; 11 and part of 12, and ERR&#x003b2;sf contains only exons 3-9, terminating at an intronic stop codon within intron 9. At the protein level (<xref ref-type="fig" rid="f1">Figure 1B</xref>), as reported previously, the ERR&#x003b2;2 protein contains 500 amino acids. The &#x02206;10 protein contains 508 amino acids; a single base frame shift that occurs upon exon 10 exclusion leads to a carboxy-terminal extension of the LBD with less than 5% homology and notable secondary structure differences between it and that of &#x003b2;2 (<xref ref-type="fig" rid="f1">Figure 1C</xref>). The ERR&#x003b2;sf protein is 433 amino acids in length, which is identical to the corresponding domains of ERR&#x003b2;2 and &#x00394;10 and highly homologous to the mouse and rat ERR&#x003b2; proteins. In other nuclear receptors, carboxyl terminal extensions known as F domains modulate receptor function and expression [<xref rid="r69" ref-type="bibr">Patel and Skafar, 2015</xref>; <xref rid="r80" ref-type="bibr">Skafar and Zhao, 2008</xref>]. cDNA exogenous expression studies with ERR&#x003b2;2, ERR&#x003b2;sf, and &#x00394;10 suggest that these have differing degrees of transcriptional activity on ERE-containing promoter-reporter constructs, and that ERR&#x003b2;2 shows a greater propensity to localize to the cytoplasm when transfected into COS-1 cells [<xref rid="r114" ref-type="bibr">Zhou et al., 2006</xref>]. By contrast, ERR&#x003b2;sf and &#x00394;10 are almost exclusively nuclear-localized. All three ERR&#x003b2; variants contain a nuclear localization sequence (NLS) in their hinge region or D domain (amino acids 173-190), and Zhou et al. speculate that the F domain of ERR&#x003b2;2, but not &#x00394;10, counteracts the function of the NLS. It is also interesting to note that while isolating ERR&#x003b2; from a human kidney cDNA library for the creation of tagged LBD constructs used to characterize synthetic ERR ligands, [<xref rid="r21" ref-type="bibr">Coward et al., 2001</xref>] specifically state that the F domain was excluded from the final GST-ERR&#x003b2; to improve recombinant protein expression. Sequence analysis of the reverse primer used to isolate that cDNA suggests that it is ERR&#x003b2;2.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><title>ERR&#x003b2; splice variants.</title><p>A, ERR&#x003b2; mRNA. The ESRRB gene produces three distinct splice variants through inclusion or exclusion of carboxyl terminal exons. UCSC Genome Browser identifiers for each transcript are shown. B, ERR&#x003b2; proteins. ERR&#x003b2;sf, ERR&#x003b2;2, and ERR&#x003b2;-&#x00394;10 variants and corresponding amino acid (aa) differences are shown to scale along with Online Mendelian Inheritance in Man (OMIM) identifiers. C, Functional domains. Common amino acids 1-432 contain well-established DNA- and ligand-binding domains (DBD, LBD). Amino acid sequences and Phyre structural predictions [<xref rid="r45" ref-type="bibr">Kelley and Sternberg, 2009</xref>] of the divergent carboxyl terminal F domains of &#x003b2;2 and &#x00394;10 are enlarged.</p></caption><graphic xlink:href="nrs-14-002-g1"/></fig><p>Through the use of variant-specific primers, Zhou et al. showed that ERR&#x003b2;sf is expressed in a broad range of human fetal and adult tissues, while ERR&#x003b2;2 and &#x00394;10 are restricted to testis and kidney. However, their analysis of genomic data for other species, including rodents, zebrafish [<xref rid="r4" ref-type="bibr">Bardet et al., 2004</xref>], dogs, and chickens, finds no evidence of sequences corresponding to carboxyl terminal exons 10-12 in these lower organisms. These data strongly suggest that 3&#x02019; AS of ERR&#x003b2; is a primate-specific event. This assertion has held up over time as other genomes have been sequenced, e.g. those of killifish and pig [<xref rid="r87" ref-type="bibr">Tarrant et al., 2006</xref>; <xref rid="r110" ref-type="bibr">Yang et al., 2015</xref>], which show or predict protein products equivalent to ERR&#x003b2;sf.</p></sec><sec><title>Annotation errors and the challenge of assessing human ESRRB expression in public gene expression data</title><p>The proliferation of large-scale transcriptomic studies, and the publicly-available data they generate, have potential to broaden our knowledge of ERR&#x003b2; function in contexts where it has not yet been directly studied. However, erroneous use of the 3&#x02019; UTR from hERR2 (GenBank ID X51417.1) &#x02013; known to be rat ERR&#x003b2; [<xref rid="r15" ref-type="bibr">Chen et al., 1999</xref>] &#x02013; for probeset design on human versions of the most popular gene expression profiling platforms is a significant source of confusion. Table 2 shows<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Human ESRRB probeset errors on popular gene expression profiling platforms</title></caption><table frame="hsides" rules="groups"><col width="14.54%" span="1"/><col width="20.22%" span="1"/><col width="30.89%" span="1"/><col width="34.35%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Source</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Probeset ID</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Platform(s)</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>BLASTn Query Coverage</underline></th></tr></thead><tbody><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Affymetrix<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">207726_at<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">U133A, U133 Plus 2.0<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2, X51417.1, 100% hERR&#x003b2;2, AF094517.1, 11% ERR&#x003b2;, NM_004452.3, 14% ERR&#x003b2;sf, AY451389.1, 2% ERR&#x003b2;-&#x00394;10, AY451390.1, 2% *Zero hits from Human Genomic+Transcript<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">160036_at<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">U95, U95A-Av2, U95B-E<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2, X51417.1, 100% hERR&#x003b2;2, AF094517.1, 9% ERR&#x003b2;, NM_004452.3, 12% *Zero hits from Human Genomic+Transcript<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">223858_at<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">U133 Plus 2.0<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2, X51417.1, 5% hERR&#x003b2;2, AF094517.1, 100% ERR&#x003b2;, NM_004452.3, 76% ERR&#x003b2;-&#x00394;10, AY451390.1, 45% ^Multiple hits from Human Genomic+Transcript<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Agilent<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">A_23_P22183<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Human 1A Oligo Microarray v2<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2, X51417.1, 100% hERR&#x003b2;2, AF094517.1, 18% ERR&#x003b2;, NM_004452.3, 28% ERR&#x003b2;sf, AY451389.1, 18% ERR&#x003b2;-&#x00394;10, AY451390.1, 18% *Zero hits from Human Genomic+Transcript<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">A_23_P22190<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Human Genome 44K<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR2, X51417.1, 100% *Zero hits from Human Genomic+Transcript<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1"/><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">A_23_P391857</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Human 1A Oligo Microarray v2, Human Genome 44K</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">hERR&#x003b2;2, AF094517.1, 100% ERR&#x003b2;, NM_004452.3, 100% ERR&#x003b2;-&#x00394;10, AY451390.1,100% ^Multiple hits from Human Genomic+Transcript</td></tr></tbody></table></table-wrap>nucleotide Basic Local Alignment Search Tool (BLASTn) coverage of ERR&#x003b2; transcript identifiers for selected probeset IDs present on widely-reported Affymetrix and Agilent platforms; target sequences are shown in Supplementary Material. In addition to poor query coverage of known ERR&#x003b2; sequences, four of these probesets (207726_at and 160036_at for Affymetrix, A_23_P22183 and A_23_P22190 for Agilent) yield zero ESRRB-relevant hits when searched against the Human Genomic + Transcript Collection. This is in direct contrast to probesets 223858_at (Affymetrix), A_23_P391857 (Agilent) and others (not shown), which identify multiple ESRRB-relevant hits and have better query coverage. Probeset 207726_at alone is responsible for &#x0003e;37% of human ESRRB gene expression data in the Gene Expression Omnibus (GEO, 979 records out of 2597). This presents a big problem for data repurposing. End-users may unwittingly draw spurious conclusions from data derived from the wrong probeset, or find no correlation with phenotype or disease state where one might actually exist. This is particularly true for ERR&#x003b2;sf, which with respect to cDNA exogenous expression studies is arguably the best characterized, but only probesets 787_at and 54212_at (Affymetrix U95 series) or A_23_P65597 (Agilent Human 1A Oligo Microarray v2) have any coverage of this splice variant and these platforms are no longer actively produced.</p><p>The less biased nature of RNA sequencing (RNAseq) should help to alleviate these issues in the future, but only as this data type is more widely reported and raw data deposited. Table 3 shows transcript identifiers from two sources, Ensembl and the UCSC Genome Browser, for &#x00394;10, ERR&#x003b2;2, and ERR&#x003b2;sf. Ensembl (release 82) shows eight possible ESRRB transcripts, although three of these mRNAs are not predicted to make a protein. The transcript IDs that show a protein of 433 and 500 amino acids correspond to &#x003b2;sf and &#x003b2;2, respectively, even though the 500 aa ID is annotated as undergoing nonsense-mediated decay. The remaining transcript IDs all show a predicted protein of 508 amino acids, which corresponds to the length of &#x02206;10. While the first two IDs have different annotations of their exons and overall transcript length, their predicted protein contains the same 508 amino acids as the transcribed protein sequence. The last transcript ID also predicts 508 amino acids, but an alternative start site shifts the coding region upstream to include 5 additional amino acids at the beginning of the transcript. </p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Human ESRRB splice variant identifiers from UCSC Genome Browser and Ensembl</title></caption><table frame="hsides" rules="groups"><col width="25.23%" span="1"/><col width="21%" span="1"/><col width="21%" span="1"/><col width="32.77%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Database</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>ERR&#x003b2;sf</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>ERR&#x003b2;2&#x003b2;2</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>ERR&#x003b2;-&#x00394;10&#x003b2;-&#x00394;10</underline></th></tr></thead><tbody><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">UCSC Genome Browser<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">uc001xsq.1<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">uc001xso.0<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">uc001xsr.3<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Ensembl Relase 82</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ENST00000556177</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ENST00000505752</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ENST00000509242; ENST00000380887; ENST00000512784</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Tool building &#x02013; ERR&#x003b2; synthetic ligands</title><p>X-ray crystallographic structures of the LBDs of ONRs, coupled with the discovery and synthesis of small molecules that fit within their ligand-binding pocket(s), have accelerated our understanding of the function of these proteins (recently reviewed in [<xref rid="r30" ref-type="bibr">Gallastegui et al., 2015</xref>]). However, the direct study of ERR&#x003b2; in these contexts has been minimal. The LBD of the related ERR&#x003b3;, crystallized first by Greschik and colleagues [<xref rid="r35" ref-type="bibr">Greschik et al., 2004</xref>; <xref rid="r36" ref-type="bibr">Greschik et al., 2002</xref>] and refined by several other groups [<xref rid="r1" ref-type="bibr">Abad et al., 2008</xref>; <xref rid="r14" ref-type="bibr">Chao et al., 2006</xref>; <xref rid="r99" ref-type="bibr">Wang et al., 2006</xref>], is at the amino acid level ~80% identical to that of ERR&#x003b2; (reviewed in [<xref rid="r3" ref-type="bibr">Ariazi and Jordan, 2006</xref>]). More recent studies [<xref rid="r20" ref-type="bibr">Collin et al., 2008</xref>; <xref rid="r23" ref-type="bibr">Di Micco et al., 2014</xref>] have used these ERR&#x003b3; crystal structures to build homology models of the ERR&#x003b2; LBD, which to our knowledge has not yet been crystallized. Sequence alignment shows that within the ligand-binding pocket itself, only two of 19 residues differ between ERR&#x003b2; and ERR&#x003b3;: in Helix 7, Asparagine 346 of ERR&#x003b3; corresponds to Tyrosine 321 of ERR&#x003b2;; and in Helix 5, Valine 313 of ERR&#x003b3; corresponds to Isoleucine 288 of ERR&#x003b2;. Given the ~90% identity of amino acid residues within the ligand-binding pockets of ERR&#x003b3; vs. ERR&#x003b2;, it is not surprising that these receptors share several synthetic antagonists and agonists (summarized in Table 4).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Selected ERR Synthetic Ligands</title></caption><table frame="hsides" rules="groups"><col width="31.18%" span="1"/><col width="12.86%" span="1"/><col width="23.22%" span="1"/><col width="32.74%" span="1"/><thead><tr><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Compound</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Category</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Receptor(s) Targeted</underline></th><th valign="top" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1"><underline>Other Activities</underline></th></tr></thead><tbody><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Diethylstilbestrol (DES)<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Antagonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">All ERRs<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Estrogen Receptor agonist<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Resveratrol<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Antagonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">All ERRs<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Estrogen Receptor mixed agonist/antagonist<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">4-hydroxytamoxifen (4HT)<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Antagonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ERR&#x003b3;<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Estrogen Receptor antagonist; Asn vs. Tyr in LBD confers ERR&#x003b3; specificity<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">4-methylenesterols, T. swinhoei<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Antagonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ERR&#x003b2;<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Pregnane-X-Receptor agonists; Farnesoid-X-Receptor antagonists<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Bisphenol A (BPA)<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Agonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ERR&#x003b3;<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Estrogen Receptor agonist; Asn vs. Tyr in LBD confers ERR&#x003b3; specificity<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">Soy Isoflavones (genistein)<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Agonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">All ERRs<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Estrogen Receptor agonist<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">GSK4716<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Agonist<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ERR&#x003b2;, ERR&#x003b3;<hr/></td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Glucocorticoid Receptor trans-activation; Smoothened Inhibitor<hr/></td></tr><tr><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row" rowspan="1" colspan="1">DY131</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Agonist</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">ERR&#x003b2;, ERR&#x003b3;</td><td valign="top" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" rowspan="1" colspan="1">Smoothened inhibitor</td></tr></tbody></table></table-wrap><sec><title>Antagonists</title><p>The synthetic estrogen diethylstilbestrol (DES) was the first ERR&#x003b2; antagonist to be identified [<xref rid="r90" ref-type="bibr">Tremblay et al., 2001b</xref>]. For thirty years DES was used in pregnant women to prevent miscarriage, with the unintended side effects of increasing the risk of breast and vaginal cancers not only in women who received the drug, but also their female offspring [<xref rid="r37" ref-type="bibr">Harris and Waring, 2012</xref>; <xref rid="r40" ref-type="bibr">Hilakivi-Clarke, 2014</xref>]. Tremblay et al. hypothesized a connection between DES and ERR&#x003b2; based on the striking similarity between the placental phenotype of ERR&#x003b2;-null mice [<xref rid="r56" ref-type="bibr">Luo et al., 1997</xref>] (but not ERR&#x003b1;-null or double ER&#x003b1;/ER&#x003b2;-null animals) and pregnant wild type mice exposed to DES [<xref rid="r76" ref-type="bibr">Scott and Adejokun, 1980</xref>] &#x02013; in both cases, trophoblast differentiation is accelerated, leading to the accumulation of trophoblast giant cells (see below). Using a coactivator displacement assay, in which the biotinylated receptor interacting domain (RID) of steroid receptor coactivator-2 (SRC2, GRIP1) is bound to GST-tagged receptor LBDs and compounds are screened for their ability to enhance or reduce this interaction, they showed that DES is a micromolar (IC<sub>50</sub> &#x02248; 1 &#x003bc;M) antagonist for all three ERR family members. DES antagonist activity was confirmed in cell-based luciferase promoter-reporter assays. Interestingly, this study also identified resveratrol as an ERR antagonist, though a weaker one by at least an order of magnitude [<xref rid="r90" ref-type="bibr">Tremblay et al., 2001b</xref>]. The resolution of the crystal structure of the ERR&#x003b3; LBD bound to DES by Greschik et al. established that the mechanism of antagonism involves displacement of Phenylalanine 435 (common to ERR&#x003b2;) in the ligand binding pocket, which causes Helix 12 to be dislodged from the LBD [<xref rid="r35" ref-type="bibr">Greschik et al., 2004</xref>; <xref rid="r36" ref-type="bibr">Greschik et al., 2002</xref>].</p><p>4-hydroxytamoxifen (4HT) was initially identified as another ERR&#x003b2; antagonist. Coward et al. [<xref rid="r21" ref-type="bibr">Coward et al., 2001</xref>] and Tremblay et al. [<xref rid="r89" ref-type="bibr">Tremblay et al., 2001a</xref>] again used coactivator displacement assays (GST-tagged receptor LBDs and either biotinylated SRC1.2 or receptor interacting protein 140 (RIP140), respectively) to show that 4HT could disrupt receptor/coactivator interaction. However, both groups observed that 4HT is 3-5 times more potent on the LBD of ERR&#x003b3; than ERR&#x003b2;, and Coward et al. report that despite the ability of 4HT to disrupt ERR&#x003b2; LBD interactions with the SRC1.2 peptide <italic>in vitro</italic>, it can not do so in a mammalian two-hybrid assay in intact cells [<xref rid="r21" ref-type="bibr">Coward et al., 2001</xref>]; these data suggest that 4HT is not a true ERR&#x003b2; antagonist. The resolution of the crystal structure of the ERR&#x003b3; LBD bound to 4HT by Greschik et al. shows that, like DES, it alters the conformation of Helix 12, though it does so by steric hindrance owing to the long side chain of 4HT rather than displacement of a conserved phenylalanine [<xref rid="r35" ref-type="bibr">Greschik et al., 2004</xref>; <xref rid="r36" ref-type="bibr">Greschik et al., 2002</xref>]. The selective antagonist activity of 4HT for ERR&#x003b3; has now been specifically linked to one of the two amino acids that differ between it and ERR&#x003b2; within the ligand-binding pocket; mutation of Asparagine 346 in ERR&#x003b3; to Tyrosine (the corresponding amino acid in ERR&#x003b2;) reduces 4HT binding affinity by 4-fold [<xref rid="r50" ref-type="bibr">Liu et al., 2014</xref>], identical to the difference in potency observed in [<xref rid="r21" ref-type="bibr">Coward et al., 2001</xref>; <xref rid="r89" ref-type="bibr">Tremblay et al., 2001a</xref>]. This substitution also significantly impairs binding of the endocrine disruptor bisphenol A (BPA), which is an ERR&#x003b3; (but not ERR&#x003b2;) agonist [<xref rid="r85" ref-type="bibr">Takayanagi et al., 2006</xref>], further implicating Tyrosine 321 as a key structural determinant of synthetic ligand specificity for ERR&#x003b2; vs. ERR&#x003b3;.</p><p>Di Micco et al. recently combined homology models of the ERR&#x003b2; LBD with GAL4-luciferase assays to identify a group of 4-methylenesterols, natural products isolated from the marine sponge Theonella swinhoei, as antagonists for all three ERRs [<xref rid="r23" ref-type="bibr">Di Micco et al., 2014</xref>]. These compounds also modulate the activity of other ONRs, including pregnane-X-receptor and farnesoid-X-receptor. Additional compounds may ultimately prove to be ERR&#x003b2; antagonists, as well. For example, troglitazone and kaempferol inhibit the transcriptional activity of ERR&#x003b1; and ERR&#x003b3;, and <italic>in vitro</italic> coactivator binding to the isolated LBDs of these receptors, but ERR&#x003b2; was not specifically tested [<xref rid="r98" ref-type="bibr">Wang et al., 2009</xref>; <xref rid="r102" ref-type="bibr">Wang et al., 2010b</xref>].</p></sec><sec><title>Agonists</title><p>The soy isoflavones genistein, daidzein, and biochanin a increase coactivator recruitment to the LBD of all three ERRs, similar to their effects on classical estrogen receptors [<xref rid="r82" ref-type="bibr">Suetsugi et al., 2003</xref>]. Two highly similar synthetic small molecules are known to function more specifically as agonists of ERR&#x003b2;: GSK4716 and DY131 (also known as GSK9089) [<xref rid="r111" ref-type="bibr">Yu and Forman, 2005</xref>; <xref rid="r116" ref-type="bibr">Zuercher et al., 2005</xref>]. These acyl hydrazones differ by a single functional group - a terminal isopropyl group in GSK4716 and a terminal diethylamino group in DY131. GAL4-luciferase and ERE-luciferase assays using isolated LBDs or full-length receptors, respectively, show that both compounds increase the transcriptional activity of ERR&#x003b2; and ERR&#x003b3;, with no effect on either ERR&#x003b1; or classical estrogen receptors; Zuercher et al. also show that both molecules can compete with radiolabeled 4HT for binding to ERR&#x003b3; [<xref rid="r116" ref-type="bibr">Zuercher et al., 2005</xref>]. Subsequent resolution of the crystal structure of ERR&#x003b3; bound to GSK4716 and the RIP140 coactivator peptide identified an unexpected molecular mechanism of activation [<xref rid="r99" ref-type="bibr">Wang et al., 2006</xref>]. Like many ONRs, the ERRs are constitutively active, with Helix 12 pre-positioned in an active conformation that, together with Helices 3 and 5, forms a groove permissive for coactivator binding ([<xref rid="r22" ref-type="bibr">Darimont et al., 1998</xref>; <xref rid="r39" ref-type="bibr">Heery et al., 1997</xref>], reviewed in [<xref rid="r30" ref-type="bibr">Gallastegui et al., 2015</xref>]). GSK4716 does not alter this conformation directly, but instead shifts the position of amino acids in Helices 1 and 3, enlarging the ligand-binding pocket significantly while also increasing the stability of the LBD [<xref rid="r99" ref-type="bibr">Wang et al., 2006</xref>]; these amino acids are conserved in ERR&#x003b2;, suggesting that the mechanism of activation of this receptor by these ligands is likely similar.</p><p>Much as ERR&#x003b2; antagonists have receptor-independent activities, so too do the agonists DY131 and GSK4716. Wang et al. [<xref rid="r100" ref-type="bibr">Wang et al., 2010a</xref>] reported that GSK4716 induces expression of GR and several of its target genes in differentiated mouse skeletal muscle cells, and enhances GR-dependent transcriptional activation of a GRE-containing luciferase reporter. This seemingly contradicts the finding by Trapp and Holsboer that exogenous hERR2 (now known to be rat ERR&#x003b2;, analogous to human ERR&#x003b2;sf) inhibits GR transcriptional activity [<xref rid="r88" ref-type="bibr">Trapp and Holsboer, 1996</xref>]. However, ERR&#x003b3;-directed RNAi inhibits expression of GR and a subset of target genes in the skeletal muscle cell model, suggesting that ERR&#x003b3; is the more relevant target for GSK4716 in this setting. More recently, both agonists have been shown to function as inhibitors of Hedgehog signal transduction through direct binding to Smoothened (Smo), which prevents its Sonic hedgehog (Shh)-induced redistribution to the primary cilium and blocks downstream GLI transcriptional activation [<xref rid="r101" ref-type="bibr">Wang et al., 2012</xref>]. Ligand competition assays suggest that DY131 antagonizes wild type Smo through the same or a similar mechanism as more established inhibitors like cyclopamine and GDC-0449 (vismodegib), but is unable to suppress the oncogenic SmoM2 mutant. This initially raised the question as to whether our observation of DY131-mediated mitotic arrest in the T98G cellular model of glioblastoma (GBM; see below) is the result of Smo inhibition, but neither cyclopamine nor GDC-0449 cause this phenotype. That, coupled with reversal (and rescue) of the mitotic arrest phenotype by shRNA-mediated depletion of the ERR&#x003b2;2 splice variant (and re-expression of an shRNA-resistant cDNA in silenced cells) argues against this &#x02018;off target&#x02019; effect [<xref rid="r38" ref-type="bibr">Heckler and Riggins, 2015</xref>].</p></sec></sec><sec><title>Functions of ERR&#x003b2; in development </title><p>ERR&#x003b2; plays a critical role in the development and normal physiologic function of several tissues and organ systems in the mouse, and a specific form of nonsyndromic hearing impairment in humans. Given that most of these studies have been carried out in mice, it is important to recall that there is only one murine ERR&#x003b2;, which is homologous to the human ERR&#x003b2;sf splice variant.</p><sec><title>Placental development</title><p>[<xref rid="r71" ref-type="bibr">Pettersson et al., 1996</xref>] first reported the expression of ERR&#x003b2; in mouse conceptuses at 6.5 days post coitum (dpc) in the ectodermally derived subregion of the amniotic fold. By day 7.5 they detected ERR&#x003b2; in chorion with highest signal at the boundary between chorion and the extraembryonic ectoderm, suggesting a role in chorion formation in the placenta. At day 8.5 no expression of ERR&#x003b2; is detected in the basal part of the chorionic plate or any other part of the embryo. This expression pattern of ERR&#x003b2; disclosed a very specific spatiotemporal role of this receptor in the development of the chorion and the placenta.</p><p>Subsequent studies by [<xref rid="r56" ref-type="bibr">Luo et al., 1997</xref>] also suggest a very specific expression of ERR&#x003b2; in extra embryonic tissues during development in mice. They detect ERR&#x003b2; in the ectodermally derived region of amniotic fluid at 6.5 dpc with no expression of ERR&#x003b2; by day 9.5, again suggesting that ERR&#x003b2; plays an important role in the formation of the chorion. ERR&#x003b2;<sup>-/-</sup> mice have severe placental abnormalities and die at 10.5 dpc, asserting that ERR&#x003b2; knockout is embryonically lethal and important for placental formation. These mice show abnormal chorion development and deficiency of diploid trophoblast, which could be rescued by tetraploid wild type embryos, suggesting extra embryonic expression of ERR&#x003b2;. ERR&#x003b2; (i.e., ERR&#x003b2;sf) therefore seems to be important in mediating critical function of chorion and terminal differentiation of the diploid trophoblast during placental development in mice. [<xref rid="r90" ref-type="bibr">Tremblay et al., 2001b</xref>] show that mice treated with DES from days 4.5-8.5 dpc have a similar phenotype to ERR&#x003b2; null mice, with placental abnormalities in trophoblast differentiation. DES acts as an antagonist of ERR&#x003b2; and the authors suggest that DES effects could be through the ERR&#x003b2; receptor. More recently, [<xref rid="r64" ref-type="bibr">Nagao et al., 2013</xref>] treated mice with DES and found that ERR&#x003b2; expression is observed and does not change with DES treatment. These mice did have placental abnormalities and an increase in trophoblast giant cells, as observed previously by [<xref rid="r90" ref-type="bibr">Tremblay et al., 2001b</xref>].</p><p>ERR&#x003b2; also seems to be important in differentiation of primordial germ cells (PGC) in mice. ERR&#x003b2; is expressed in embryonic tissue at day 13.5, and was detected in both male and female gonads and the brain [<xref rid="r63" ref-type="bibr">Mitsunaga et al., 2004</xref>]. However, they did not detect any ERR&#x003b2; in the placenta or any other tissues at day 13.5. This was the first report of ERR&#x003b2; expressed in embryonic tissues and not just extra embryonic tissues as reported by [<xref rid="r71" ref-type="bibr">Pettersson et al., 1996</xref>] and [<xref rid="r56" ref-type="bibr">Luo et al., 1997</xref>]. ERR&#x003b2; expression in PGCs is diminished by day 15.5, again suggesting a very transient expression and role of ERR&#x003b2; in germ cell differentiation. ERR&#x003b2;<sup>-/-</sup> mice, when rescued by triploid wild type embryos, were normal and fertile but the proliferation of PGCs was affected as determined by staining for Ki67 and Mitotic Protein Monoclonal #2 (MPM2), which detects mitotic phosphorylation of multiple proteins. ERR&#x003b2; therefore plays an important role PGCs proliferation during development. Interestingly, these mice have behavioral defects (particularly the females), implying that ERR&#x003b2; could play a role in the brain.</p><p>Recently, [<xref rid="r47" ref-type="bibr">Kumar and Mendelson, 2011</xref>] reported that the family member ERR&#x003b3; is induced during syncytiotrophoblast differentiation and requires oxygen. ERR&#x003b3; in turn induces the expression of the hCYP19I.1 gene by binding to its promoter. They did not, however, find any expression of any of the isoform of ERR&#x003b2; in human trophoblast or differentiated placental cells. ERR&#x003b2; also did not induce the expression of hCYP19I.1 in transient transfection experiments, suggesting a more specific role for ERR&#x003b3; in human placental development, although the isoform of ERR&#x003b2; used in these experiments is not clear. This also agrees with [<xref rid="r106" ref-type="bibr">Xie et al., 2009</xref>] that ERR&#x003b2; is undetectable in human embryonic stem cells (see below). ERR&#x003b2; may therefore have a species-specific role in embryonic differentiation and placental development, as it is abundantly expressed in mouse embryonic cells but not in human embryonic cells. Also, the limited duration of ERR&#x003b2; expression in both the placenta and the embryonic PGCs suggests that ERR&#x003b2; effects are restricted to a very brief window during development and attention needs to be given to this while studying the role ERR&#x003b2; in this setting.</p></sec><sec><title>Inner ear development</title><p>[<xref rid="r16" ref-type="bibr">Chen and Nathans, 2007</xref>] first showed that ERR&#x003b2; (analogous to human ERR&#x003b2;sf) is expressed in strial marginal cells of the cochlea and the vestibular dark cells of the mouse inner ear. They generated conditional ERR&#x003b2;<sup>-/-</sup> mice that exhibit head bobbing and spinning and running in circles, suggesting a defect in vestibular function. These mice have hearing impairment and show characteristics of diminished endolymph production, suggesting the role of ERR&#x003b2; in development of inner ear. These mice also exhibit a reduction in the expression of ion channels and transporters in inner ear, emphasizing the role of ERR&#x003b2; in inner ear homeostasis, consistent with the head bobbing and loss of balance phenotype.</p><p>In humans, mutations in the ESRRB gene lead to the autosomal recessive nonsyndromic hearing impairment DFNB35. [<xref rid="r20" ref-type="bibr">Collin et al., 2008</xref>] have reported recessive nonsyndromic hearing impairment in a large consanguineous family of Turkish origin mapping to chromosome 14q24.3-q34.12 that overlaps with the DFNB35 locus previously reported in a consanguineous family from Pakistan. Linkage and mutation analyses of this region identified alterations in ESRRB exons 5-12, which were also found in the human feta cochlear cDNA library reported by [<xref rid="r55" ref-type="bibr">Luijendijk et al., 2003</xref>]. Sequence analysis identified a 7bp duplication in exon 8, which leads to a frameshift and early termination of the protein. Further mutation analysis identified missense mutations in the DNA binding (Alanine110Valine) and ligand binding domains (Leucine320Proline, Leucine347Proline, Proline342Leucine) of ERR&#x003b2;. More recently, an additional missense mutation (Proline305Histidine) in the ligand-binding domain was identified in another Tunisian family with hearing impairment [<xref rid="r6" ref-type="bibr">Ben Sa&#x000ef;d et al., 2011</xref>]. The mutants in the ESRRB found in DFNB35 deafness may also contribute to dental decay through the demineralization of the enamel surface, as reported by [<xref rid="r103" ref-type="bibr">Weber et al., 2014</xref>]. These mutations are predicted to result in structural changes in DNA binding domain and the ligand binding domain, thereby impairing the overall structural integrity of the protein or affecting the stability of the ERR&#x003b2; protein leading to functional loss. In human, these missense mutations could affect all three ERR&#x003b2; splice variants. Two new ERR&#x003b2; missense mutations - Arginine6Glycine and Arginine382Cystine &#x02013; have recently been identified by [<xref rid="r104" ref-type="bibr">Wu et al., 2015</xref>] in children with good outcomes following cochlear implant installation, and these mutations too should affect all three splice variants.</p><p>[<xref rid="r20" ref-type="bibr">Collin et al., 2008</xref>] analyzed the distribution of ERR&#x003b2; splice variants at the mRNA level in human tissues by variant-specific PCR, and found that ERR&#x003b2;sf and ERR&#x003b2;-&#x00394;10 are ubiquitously expressed in all the tissues including the cochlea, while the ERR&#x003b2;2 is found abundantly only in the testis and the cochlea, with lower expression in retina. The authors suggest that the autosomal recessive hearing impairment might be due to ERR&#x003b2;2, as it is abundantly expressed in cochlea, although they do not rule out that the other two isoforms could also contribute to the hearing impairment. Overall, ERR&#x003b2; plays an important role in development of the inner ear and hearing. The mechanism through which ERR&#x003b2; affects the hearing or function in the inner ear is not known, though it could be through cooperation with TR or GR, as both of these receptors are abundantly expressed in inner ear, and in cell culture studies hERR2 (rat ERR&#x003b2;sf) is known to drive transcription from TREpal [<xref rid="r107" ref-type="bibr">Xie et al., 1999</xref>] and suppress GR-mediated transcriptional activity [<xref rid="r88" ref-type="bibr">Trapp and Holsboer, 1996</xref>].</p></sec><sec><title>Retinal development</title><p>[<xref rid="r7" ref-type="bibr">Blackshaw et al., 2001</xref>; <xref rid="r8" ref-type="bibr">Blackshaw et al., 2004</xref>] reported the expression of ERR&#x003b2; (functionally, ERR&#x003b2;sf) in photoreceptors of the developing mouse retina by using serial analysis of gene expression (SAGE) and in situ hybridization techniques. They detected expression of ERR&#x003b2; in rod cells and in immature photoreceptors during the first postnatal week, but the expression diminishes by postnatal day 10 (P10). Interestingly, during retinal development, ERR&#x003b2; was expressed at markedly lower levels at prenatal stages, which is very different from its role in embryogenesis, placental development and inner ear development, where it is expressed early in embryo development. The isoform of ERR&#x003b2; detected is by definition ERR&#x003b2;sf, as this is the only form found in rodents.</p><p>[<xref rid="r66" ref-type="bibr">Onishi et al., 2010</xref>] later reported a more detailed analysis of ERR&#x003b2; expression in developing and mature mouse retina. They showed that ERR&#x003b2; is expressed in horizontal cells throughout the first week postnatally and the expression decreases by day P7, similar to what was observed previously. By day P7 they see expression of ERR&#x003b2; in the outer nuclear layer in the rod photoreceptor cells, but not in cone photoreceptors, as ERR&#x003b2; colocalized with the rod-specific marker rhodopsin. They also found that ERR&#x003b2; activated rhodopsin expression and induced expression of rod cell-specific genes such as guanylate cyclase activator proteins and sodium/potassium/calcium rod inner segment cation exchanger Slc24a1 and other genes involved in glycolysis. It is interesting that just like its function in inner ear where ERR&#x003b2; regulated ion channel homeostasis, it could play a similar role in rod photoreceptor cells by regulating an ion exchanger.</p><p>Conditional ERR&#x003b2;<sup>-/-</sup> mice have defects in the inner ear but apparently normal retinal development, which agrees with [<xref rid="r7" ref-type="bibr">Blackshaw et al., 2001</xref>; <xref rid="r8" ref-type="bibr">Blackshaw et al., 2004</xref>], where they see a very low expression of ERR&#x003b2; during prenatal stages. [<xref rid="r66" ref-type="bibr">Onishi et al., 2010</xref>] suggest that ERR&#x003b2; might play a role in regulation of rod photoreceptor cells at later ages. They found that ERR&#x003b2;<sup>-/-</sup> mice show a decrease in the number of rod photoreceptors as they age, and this could be rescued by electroporation of ERR&#x003b2;. This suggests that ERR&#x003b2; might have a role in maintaining the rod photoreceptor cells and their function in adults. The authors also suggest that certain individuals lacking ERR&#x003b2; might suffer from late onset rod photoreceptor degeneration.</p><p>[<xref rid="r79" ref-type="bibr">Sharon et al., 2002</xref>] have reported the expression of ERR&#x003b2; mRNA in human retinal tissues. However, it is not clear which isoform of ERR&#x003b2; they detected, though [<xref rid="r20" ref-type="bibr">Collin et al., 2008</xref>] have shown expression of the ERR&#x003b2;2 splice variant to be higher in retinal vs. most other human tissues. Overall, ERR&#x003b2; seems to play an important role in the maintenance of rod photoreceptors and expression of rod-specific genes in mice, while the role of ERR&#x003b2; in the human retina remains to be fully elucidated.</p></sec></sec><sec><title>Functions of ERR&#x003b2; in the central nervous system and hypothalamic-pituitary axis</title><p> In their genome-wide atlas expression study of adult mouse brain, [<xref rid="r49" ref-type="bibr">Lein et al., 2007</xref>] report that ERR&#x003b2; (i.e., ERR&#x003b2;sf) is expressed in the hindbrain. [<xref rid="r73" ref-type="bibr">Real et al., 2008</xref>] performed a subsequent, more detailed study of ERR&#x003b2; in postnatal and adult mouse brain. Using four different antibodies for ERR&#x003b2; immunostaining, they show that ERR&#x003b2; is expressed in hypothalamic suprachiasmatic nucleus, ventral and dorsal geniculate nuclei, pretectal nuclei, superior colliculus, and thalamic posterior nucleus. Most of these regions are targets of retinal projections. This study also shows ERR&#x003b2; expression in mouse retinal ganglion cells and along the course of retinal axons in the retinorecipient nuclei. Here, ERR&#x003b2; is detected in both the cytoplasm and nucleus by one of four antibodies used, but the other three antibodies detected only nuclear staining and hence cannot visualize axon fibers. The cytoplasmic expression of ERR&#x003b2; in axon fibers should be studied further. ERR&#x003b2; expression in the hypothalamic suprachiasmatic nucleus may suggest that ERR&#x003b2; plays a role in control of circadian rhythm.</p><p>The expression of ERR&#x003b2; along the efferent retinal projections also agrees with the fact that ERR&#x003b2; plays an important role in maintenance and function of rod photoreceptors, as discussed above in [<xref rid="r66" ref-type="bibr">Onishi et al., 2010</xref>]. The expression of ERR&#x003b2; in horizontal cells of retina, which are targets of retinal ganglion cells that also express ERR&#x003b2;, suggests a comprehensive role for ERR&#x003b2; in mouse retinal development, though connections between these need to be explored further.</p><p>[<xref rid="r11" ref-type="bibr">Byerly et al., 2013a</xref>] recently showed that ERR&#x003b2; conditional knockout mice have lower body weights, decreased fat mass, increased metabolic activity and increased energy expenditure, and these differences were observed even at resting metabolic states, suggesting deletion of ERR&#x003b2; affects energy homeostasis in addition to the vestibular defects observed by [<xref rid="r16" ref-type="bibr">Chen and Nathans, 2007</xref>]. These mice also had altered food intake with decreased inter-meal interval, decreased inter-meal satiety ratio and an overall increase in meal number and size. They created a selective knockout of ERR&#x003b2; (Nestin-Cre: ERR&#x003b2;<sup>lox/lox</sup> in the hindbrain of the mice, where ERR&#x003b2; is predominantly expressed in the brain [<xref rid="r49" ref-type="bibr">Lein et al., 2007</xref>]. These mice have selectively lower expression of ERR&#x003b2; in the hindbrain and display similar phenotypes to whole-body ERR&#x003b2; knockout mice with respect to inter-meal satiety ratio and interval, body weight and metabolic activity. They also have decreased expression of neuropeptide Y (NPY), which is involved in the control of appetite and body weight gain, and had increased insulin sensitivity and lower blood glucose levels. Interestingly, they found that ERR&#x003b3; played a compensatory role in food intake and homeostasis when ERR&#x003b2; is knocked out. The expression of ERR&#x003b3; is enhanced in ERR&#x003b2;<sup>-/-</sup> mice and in Nestin-Cre:ERR&#x003b2;<sup>lox/lox</sup> mice. When the wild type and ERR&#x003b2;<sup>-/-</sup> mice were treated with DY131, a selective agonist of ERR&#x003b2; and ERR&#x003b3;, the wt mice displayed similar phenotypes as ERR&#x003b2;<sup>-/-</sup> and the ERR&#x003b2;<sup>-/-</sup> had further decreases in intra-meal satiety and intra-meal intervals and the expression of NPY. These data suggest that ERR&#x003b3; can regulate some aspects of food intake in the absence of ERR&#x003b2;. Together, they both may play an important role in regulating the expression of each other and whole body energy balance and food intake.</p><p>In a second paper, [<xref rid="r12" ref-type="bibr">Byerly et al., 2013b</xref>] report the effect of ERR&#x003b2; on response to restrain stress and the hypothalamic-pituitary axis (HPA) with the same animal model system, with the addition of heterozygous-null (Sox2-Cre:ERR&#x003b2;<sup>+/-</sup> mice. The heterozygous mice have increased fat mass compared to wt, but homozygous knockout have decreased fat mass and lean mass compared to wt. Surprisingly, the heterozygous mice and homozygous mice do not have any differences in inter-meal satiety ratio, but homozygous mice have lower inter-meal intervals. NPY expression is increased in the heterozygous mice compared to wt, but the highest expression is in the homozygous mice, again suggesting that ERR&#x003b2; might play an important role in expression of NPY. Considering that heterozygous vs. homozygous deletion of ERR&#x003b2; have opposing effects on fat mass, this expression pattern of NPY is interesting. The authors speculate that increased fat mass in heterozygous mice is due to increased expression NPY, while in homozygous mice the increased expression of NPY is a secondary effect in response to decreased fat mass.</p><p>Acoustic startle tests also show clear differences between heterozygous and homozygous ERR&#x003b2; knockout animals. Wild type mice had increased cortisone levels in response to stress that returned to baseline after 1 h of recovery. The heterozygous mice have strong response to stress and show elevated cortisone levels compared to wild type animals, and the recovery time was similar between them. The homozygous mice, however, have elevated baseline levels and show no increase in cortisone levels in response to stress; in fact, the cortisone levels decrease in response to stress. The elevated cortisone baseline levels correlated with elevated in situ hybridization staining for Crh (corticotrophin releasing hormone) in the homozygous mice, suggesting ERR&#x003b2; plays a role in expression of Crh. When the homozygous animals were treated with DY131 there was a small increase in Crh levels in these mice, suggesting that ERR&#x003b3; can contribute to Crh expression depending on the levels of ERR&#x003b2;. The expression levels of ERR&#x003b3; in heterozygous mice is unknown. When the Nestin-Cre:ERR&#x003b2; mice were subjected to acoustic startle response, these mice showed increased response in this test with a decreased expression of Crh. Therefore, ERR&#x003b2; might play an important role in the excitatory pathway associated with acoustic startle response. They also showed decrease in corticotrophin releasing hormone 2 (Crhr2), further suggesting that ERR&#x003b2; plays a role in modulating the hypothalamic axis and the response to stress together with ERR&#x003b3;.</p><p>The glucocorticoid receptor is a potential contributor to the effects of ERR&#x003b2; (and possibly ERR&#x003b3;) in the HPA. As discussed above, ERR&#x003b2; (hERR2, rat ERR&#x003b2;) inhibits the transcriptional activity of glucocorticoid receptor (GR). The mechanism for transcriptional inhibition of GR by ERR&#x003b2; is unknown, though ERR&#x003b2; does not bind to GRE elements or inhibit the binding of GR to DNA, suggesting that it might function as a trans suppressor of GR activity [<xref rid="r88" ref-type="bibr">Trapp and Holsboer, 1996</xref>]. On the other hand, ERR&#x003b3; induces the expression of GR and also promotes the activity of GR [<xref rid="r100" ref-type="bibr">Wang et al., 2010a</xref>]. It is interesting that ERR&#x003b2; and ERR&#x003b3;, similar in so many ways, have opposing effects on GR activity. Together, ERR&#x003b2; or ERR&#x003b3; may contribute to HPA control through their regulation of glucocorticoid receptor and other genes involved in Crh release. In addition, [<xref rid="r74" ref-type="bibr">Ren et al., 2011</xref>] show that ERR&#x003b2; along with ERR&#x003b1; and ERR&#x003b3; can induce monoamine oxidase, an enzyme that is involved in oxidative de-amination of dopamine. They further find that Parkin, an E3 ubiquitin ligase, binds to all three ERRs and promotes their degradation via the ubiquitin-proteasome pathway. Aberrant ERR&#x003b2; expression and function may therefore contribute to Parkinson&#x02019;s disease, though to our knowledge this has yet to be specifically studied.</p></sec><sec><title>Functions of ERR&#x003b2; in stem cell biology</title><p> Since the cloning and earliest functional studies of murine ERR&#x003b2;, data have pointed to a role for this receptor in regulating the balance between pluripotency and differentiation (e.g., [<xref rid="r56" ref-type="bibr">Luo et al., 1997</xref>; <xref rid="r71" ref-type="bibr">Pettersson et al., 1996</xref>; <xref rid="r90" ref-type="bibr">Tremblay et al., 2001b</xref>]), and this is one area in which the contributions of ERR&#x003b2; have been comprehensively summarized by [<xref rid="r68" ref-type="bibr">Papp and Plath, 2012</xref>], whose efforts we do not seek to duplicate here. As in the section above, it is important to recall that the mouse has one form of ERR&#x003b2;, homologous to human ERR&#x003b2;sf.</p><p>Seminal papers by [<xref rid="r43" ref-type="bibr">Ivanova et al., 2006</xref>], [<xref rid="r51" ref-type="bibr">Loh et al., 2006</xref>], and [<xref rid="r113" ref-type="bibr">Zhou et al., 2007a</xref>] (GSE4679) identified ERR&#x003b2; as an essential pluripotency factor in mouse embryonic stem cells (ESCs), a transcriptional target of Oct4 and Nanog whose RNAi-mediated depletion leads to differentiation, and a key regulatory partner for Oct4, Nanog, and Sox2. It is now known that Dax1, another ONR, is an ERR&#x003b2; target gene in mouse ESCs and establishes a negative feedback loop through direct repression of ERR&#x003b2; transcriptional activity [<xref rid="r93" ref-type="bibr">Uranishi et al., 2013</xref>]. Chromatin immunoprecipitation and sequencing (ChIP-seq) by [<xref rid="r17" ref-type="bibr">Chen et al., 2008</xref>] has identified genome-wide binding sites for ERR&#x003b2; in mouse ESCs. This ERR&#x003b2; ChIP-seq dataset (GSE11431) has been subsequently used to develop novel methods for predicting gene expression in this cell type [<xref rid="r67" ref-type="bibr">Ouyang et al., 2009</xref>], and as validation for histone modification-directed ChIP-mass spectrometry that show widespread enhancer binding by ERR&#x003b2; in mouse embryonic stem cells [<xref rid="r25" ref-type="bibr">Engelen et al., 2015</xref>]. By contrast, [<xref rid="r106" ref-type="bibr">Xie et al., 2009</xref>] demonstrate that while ERR&#x003b2; mRNA is highly expressed in mouse ESCs, it is undetectable in human ESCs. However, even in the mouse, not all stem cells are created equal, and in trophoblast stem cells (TSCs) ERR&#x003b2; is a target of FGF signaling, causing its recruitment to a distinct repertoire of target genes and association with distinct coregulatory proteins vs. ESCs [<xref rid="r48" ref-type="bibr">Latos et al., 2015</xref>]. Specifically, ERR&#x003b2; is enriched at the promoters of Eomes and Elf5 in TSCs, and mass spectrometry analysis of ERR&#x003b2; binding partners in ESCs vs. TSCs shows specific interaction with the histone-modifying (demethylase) enzyme Lsd1 and the Integrator complex in TSCs vs. SWI/SNF and the Mediator complex in ESCs. This suggests that ERR&#x003b2; makes previously unappreciated contributions to epigenetic regulation through histone demethylation in conjunction with its direct transcriptional activity.</p><p>[<xref rid="r27" ref-type="bibr">Feng et al., 2009</xref>] elegantly showed that ERR&#x003b2; can substitute for c-Myc and Klf4 in the reversion of mouse fibroblasts to induced pluripotent stem cells (iPSCs) (GSE13190). They further show that ERR&#x003b3;, but not ERR&#x003b1;, can replace murine ERR&#x003b2; in iPSC reprogramming. Interestingly, exogenous expression of Gli family zinc finger 1 (GLIS1) can enhance reprogramming in mouse and human iPSCs, but only in mouse iPSCs is this accompanied by an induction of ERR&#x003b2; [<xref rid="r60" ref-type="bibr">Maekawa et al., 2011</xref>]. Coupled with the absence of ERR&#x003b2; expression in human ESCs [<xref rid="r106" ref-type="bibr">Xie et al., 2009</xref>] and the fact that ERR&#x003b2; appears to be relevant to porcine iPSC reprogramming [<xref rid="r46" ref-type="bibr">Kues et al., 2013</xref>], these data suggest that ERR&#x003b2; is a non-primate regulator of pluripotency. A trio of papers later shed light on the molecular mechanism(s) of ERR&#x003b2; function in mouse cell pluripotency. ERR&#x003b2; is a direct target of the Wnt signaling pathway during reprogramming, can substitute for Nanog in this process, and requires a specific coactivator (nuclear receptor coactivator 3 (NCOA3), or amplified in breast cancer 1, AIB1) to exert these effects [<xref rid="r28" ref-type="bibr">Festuccia et al., 2012</xref>; <xref rid="r62" ref-type="bibr">Martello et al., 2012</xref>; <xref rid="r70" ref-type="bibr">Percharde et al., 2012</xref>], and this latter point was supported by a subsequent study [<xref rid="r105" ref-type="bibr">Wu et al., 2012</xref>]. Either ERR&#x003b2; or Nanog can promote pluripotency in ES cells depleted of nucleostemin [<xref rid="r44" ref-type="bibr">Katano et al., 2015</xref>] (GSE56797).</p><p>A unique feature of stem or pluripotent cells is altered regulation of cell cycle checkpoints, an area in which we now know ERR&#x003b2; plays an important role (at least in the mouse). In differentiated cells, a robust G1/S checkpoint is required to prevent cell cycle transit in the presence of DNA damage [<xref rid="r19" ref-type="bibr">Ciccia and Elledge, 2010</xref>]. However, in mouse ESCs, G1 phase is very short and undergoes differentiation-mediated lengthening. [<xref rid="r95" ref-type="bibr">van der Laan et al., 2013</xref>] elegantly showed that expression of the phosphatase Cdc25A remains elevated in mouse ESCs that have experienced DNA damage, tracing this back to maintenance of the deubiquitinating enzyme Dub3 that is a direct transcriptional target of ERR&#x003b2;. ERR&#x003b2; knockdown in and DY131 stimulation of mouse ESCs reduces or enhances Dub3 and Cdc25A, respectively, and RNAi-mediated inhibition of Dub3 or Cdc25A led these cells to differentiate. [<xref rid="r94" ref-type="bibr">van der Laan et al., 2014</xref>] went on to show that Dub3 expression fluctuates with the cell cycle and is upregulated during S phase in mouse ESCs, but that this is not due to concomitant changes in the expression of ERR&#x003b2;. Instead, increased expression of the p160 family of nuclear receptor coactivators, and in particular NCOA1, precedes that of Dub3 and is a key regulatory partner for ERR&#x003b2; in this context. NCOA1 is itself subject to alternative splicing, and the authors demonstrate that both splice variants of this coactivator are able to stimulate ERR&#x003b2; transcriptional activity and Dub3 expression.</p><p>Using RNAseq, [<xref rid="r53" ref-type="bibr">Lu et al., 2015a</xref>] have recently analyzed gene expression in NIH3T3 mouse embryo fibroblasts stably expressing exogenous ERR&#x003b2;sf in the absence or presence of Hedgehog ligand-containing conditioned medium (GSE71209). The rationale for this study was to clarify the functional relationship between ESRRB and Hedgehog signaling by identifying ERR&#x003b2; targets within Hedgehog signal transduction pathways. One hundred nine (109) Hedgehog-regulated mRNAs are modulated by ERR&#x003b2; overexpression &#x02013; some genes (Stmn1, Top2a, Hoxd8) are increased in an additive fashion, while for others (Igf1, Smoc2) the relationship between ERR&#x003b2; and Hedgehog ligand is antagonistic.</p></sec><sec><title>Functions of ERR&#x003b2; in human cancer</title><p>A growing number of studies suggest a tumor suppressive role for ERR&#x003b2; in human cancers, which seemingly contradicts its ability to promote pluripotency and stemness in the mouse. Initially studied in hormone-dependent tumor types, ERR&#x003b2; splice variants and fusion genes are emerging as contributors to non-epithelial malignancies, though further studies will be required to fully characterize the mechanism(s) by which this occurs.</p><sec><title>Prostate cancer</title><p> [<xref rid="r18" ref-type="bibr">Cheung et al., 2005</xref>] first reported that unlike other ERR family members, ERR&#x003b2; is restricted to normal prostate epithelial cells and some immortalized prostate lines, though it is not clear from the antibody used which ERR&#x003b2; splice variant(s) is/are being detected. Shortly after alternative splicing of ERR&#x003b2; became known, [<xref rid="r112" ref-type="bibr">Yu et al., 2008</xref>] reported the expression of ERR&#x003b2; splice variants in normal immortalized and prostate cancer cell lines by PCR, and performed functional studies using ERR&#x003b2;sf cDNAs. The short form splice variant of ERR&#x003b2; (ERR&#x003b2;sf) was expressed in all cell lines, while the other two isoforms, ERR&#x003b2;2 and ERR&#x003b2;-&#x00394;10, were not expressed in any. Confirming prior studies, expression of the ERR&#x003b2;sf was found to be higher in normal immortalized prostate cell lines than the prostate cancer cell lines. By immunohistochemistry [<xref rid="r112" ref-type="bibr">Yu et al., 2008</xref>] further demonstrate that ERR&#x003b2; is expressed in the nucleus of the epithelial cells and the stromal cells in fetal and pubertal prostate cells, and that expression is decreased with age in adult and aged prostates. ERR&#x003b2; expression is also downregulated in prostate cancer cells and in premalignant and malignant lesions in clinical prostatic tissues. Ectopic expression of ERR&#x003b2;sf inhibits the growth of LnCAP and DU145 prostate cancer cell lines through the induction of S phase cell cycle arrest, but not apoptosis, and this can be enhanced by the addition of DY131. Further, they report that ERR&#x003b2;sf activates the p21 promoter, as previously shown by [<xref rid="r13" ref-type="bibr">Castet et al., 2006</xref>], and that deletion of the first zinc finger of the DNA binding domain blunts this transcriptional activation. [<xref rid="r29" ref-type="bibr">Fujimura et al., 2010</xref>] have shown that expression of ERR&#x003b2; and ERR&#x003b3; are significantly higher in benign foci vs. cancerous lesions in prostate tissues. However, they find no correlation of ERR&#x003b2; with the clinical outcome of prostate cancer. Similar to [<xref rid="r18" ref-type="bibr">Cheung et al., 2005</xref>], the antibody used to detect ERR&#x003b2; by immunohistochemistry recognizes an epitope common to all the three splice variants, so it is not clear which variant is being detected in prostate tissues.</p><p>[<xref rid="r54" ref-type="bibr">Lu et al., 2015b</xref>] subsequently used the DU145 prostate cancer model to identify new ERR&#x003b2; target genes (GSE71208). Cells stably expressing exogenous ERR&#x003b2;sf or the empty vector control were treated with DY131 or vehicle control, and RNAseq was used to identify differentially-expressed targets. Interestingly, DY131 alone had no effect on gene expression in the absence of ERR&#x003b2; exogenous expression, while ERR&#x003b2; alone or in combination with DY131 could either upregulate or downregulate putative targets.</p></sec><sec><title>Uterine cancer</title><p> Using splice variant-specific PCR primers, [<xref rid="r10" ref-type="bibr">Bombail et al., 2008</xref>] have shown that ERR&#x003b2;sf and ERR&#x003b2;2 (referred to as &#x02018;long form&#x02019; or ERR&#x003b2;L in this publication) are expressed in normal human endometrium, with ERR&#x003b2;-&#x00394;10 not detected. ERR&#x003b2; mRNA levels were specifically quantified at different stages of the menstrual cycle: menstrual, proliferative, early secretory, mid-secretory and late secretory. There were no statistically significant differences between samples observed, though there is a trend towards higher levels in the proliferative and early secretory stages. This study also reported the detection of ERR&#x003b2; protein in early stage endometrial cancers by immunohistochemistry. Though the antibody used clearly recognizes the ERR&#x003b2;sf exogenously expressed control and exhibits nuclear staining in human tissues, it is not possible to specifically state which endogenous splice variant(s) are being detected.</p><p>[<xref rid="r9" ref-type="bibr">Bombail et al., 2010</xref>] went on to functionally characterize exogenous ERR&#x003b2;sf and ERR&#x003b2;2 (again referred to as &#x02018;long form,&#x02019; or ERR&#x003b2;L) in the ER&#x003b1;-positive Ishikawa endometrial cancer cell line. A key finding of this study is the first demonstration that ERR&#x003b2; splice variants have differential effects on the transcriptional activity of classical estrogen receptors, in this case ER&#x003b1;. Exogenous ERR&#x003b2;2 enhances estrogen-induced ER&#x003b1; activity at an ERE-luciferase reporter, while ERR&#x003b2;sf attenuates ER&#x003b1; activity. Using yellow fluorescent protein (YFP)-tagged ERR&#x003b2; expression constructs and fluorescent recovery after photobleaching (FRAP), they show that ERR&#x003b2;2 and ERR&#x003b2;sf, have different intranuclear mobility, with ERR&#x003b2;2 fluorescence recovery being significantly slower. Fluorescence resonance energy transfer (FRET) further implies a physical association between exogenous ERR&#x003b2;2 and endogenous ER&#x003b1; in response to estrogen. In this study, YFP-ERR&#x003b2;2 is reported to have predominantly nuclear localization, which the authors point out is different from the initial report by [<xref rid="r114" ref-type="bibr">Zhou et al., 2006</xref>] where ERR&#x003b2;2 is largely cytoplasmic. It is not clear whether cell type-specific factors or the YFP epitope tag contributes to this differential localization.</p><p>ERR&#x003b2;sf, which abrogates ER&#x003b1;-driven transcriptional activity in Ishikawa cells [<xref rid="r9" ref-type="bibr">Bombail et al., 2010</xref>], also physically interacts with and leads to the downregulation of NF-E2 Related Factor 2 (Nrf2), a key player in the oxidative stress response in this model system [<xref rid="r115" ref-type="bibr">Zhou et al., 2007b</xref>]. More recently, [<xref rid="r108" ref-type="bibr">Yamamoto et al., 2012</xref>] show that DY131 inhibits the growth of ER&#x003b1;-positive Ishikawa cells, but stimulates that of ER&#x003b1;-negative HEC1A endometrial cancer cells. The authors do not directly address the potential role of ERR&#x003b2;, though they present evidence that ERR&#x003b3; exogenous expression phenocopies the effects of DY131 and conclude that ERR&#x003b3; is therefore the relevant receptor in this context. Further studies are warranted to better define the role of endogenous ERR&#x003b2; splice variants in endometrial cancer.</p></sec><sec><title>Breast</title><p>All three ERRs, when exogenously expressed, are capable of inducing transcription of the estrogen-inducible gene pS2 via the ERE and ERRE in the promoter region [<xref rid="r52" ref-type="bibr">Lu et al., 2001</xref>]. This occurs not only in HeLa cells, but also ER&#x003b1; positive and negative breast cancer cells, with ERR&#x003b2;sf (rat ERR&#x003b2;) being the most potent inducer. [<xref rid="r2" ref-type="bibr">Ariazi et al., 2002</xref>] subsequently utilized quantitative PCR to determine the mRNA levels of the ERRs in human breast tissues and normal mammary epithelium controls; analysis of their ERR&#x003b2; reverse primer suggests that this primer pair detects all three ERR&#x003b2; splice variants. ERR&#x003b2; expression was found to be very low, though in this set of samples it is positively associated with expression of ER&#x003b2; and inversely associated with the fraction of cells in S phase. Using RNAseq data from The Cancer Genome Atlas (TCGA), [<xref rid="r31" ref-type="bibr">Garattini et al., 2016</xref>] show that ESRRB expression (referred to in the manuscript as NR3B2) is significantly reduced in breast tumors vs. normal breast tissue, with lowest expression in the Luminal B and Basal-Like molecular subtypes. These analyses do not appear to distinguish amongst the different ERR&#x003b2; splice variants.</p><p>[<xref rid="r78" ref-type="bibr">Sengupta et al., 2014</xref>] and [<xref rid="r86" ref-type="bibr">Tanida et al., 2015</xref>] recently published two interesting studies with more mechanistic data on the role of exogenously expressed ERR&#x003b2; splice variants in breast cancer. Sengupta et al. used the YFP-ERR&#x003b2;2 obtained from [<xref rid="r9" ref-type="bibr">Bombail et al., 2010</xref>] (and therefore it is referred to in the manuscript as &#x02018;long form,&#x02019; or ERR&#x003b2;L), while Tanida et al. used a rat ERR&#x003b2; cDNA (&#x02248; ERR&#x003b2;sf). Both groups find that each isoform of ERR&#x003b2; can form a complex with ER&#x003b1;, with [<xref rid="r78" ref-type="bibr">Sengupta et al., 2014</xref>] further demonstrating that ERR&#x003b2;2 can interact with ER&#x003b2;, as well. [<xref rid="r86" ref-type="bibr">Tanida et al., 2015</xref>] map the ER&#x003b1; interaction region of ERR&#x003b2;sf to the amino terminus (amino acids 1-92), show that ERR&#x003b2;sf attenuates ER&#x003b1;-mediated transcriptional activity and estrogen-stimulated (but importantly, not basal) MCF7 cell proliferation, and postulate that this is due to restriction of intranuclear mobility of ER&#x003b1; and/or competition for coregulatory proteins, i.e., ERR&#x003b2; is a direct corepressor of ER&#x003b1;. [<xref rid="r78" ref-type="bibr">Sengupta et al., 2014</xref>] performed coimmunoprecipitation experiments with wild type ERR&#x003b2;2 and ER&#x003b1; in MCF7 cells, in which they find that complex formation is inhibited by estradiol, and with ERR&#x003b2;2 and ER&#x003b2; in MDA-MB-231 cells, which is also attenuated by estradiol. In silico 3D molecular modeling approaches suggest that the LBD of ERR&#x003b2; (selected amino acids from 400 to 429) participates in interactions with ER&#x003b2;, but that ERR&#x003b2;/ER&#x003b1; complex formation involves the hinge region or D domain of ERR&#x003b2; (selected amino acids from 179 to 234). The predictions of these models have not yet been validated by site-directed mutagenesis, which will be required to confirm how these receptors interact <italic>in vivo</italic> and to resolve differences between these computational models and direct demonstration by Tanida and colleagues that the amino terminus of ERR&#x003b2; is required for ER&#x003b1; binding. Finally, it is interesting to note that exogenous expression of ERR&#x003b2;sf can apparently suppress the proliferation of a triple negative breast cancer cell line MRK-nu-1 (data not shown, [<xref rid="r86" ref-type="bibr">Tanida et al., 2015</xref>]) while having no effect on MCF7 cell growth in the absence of estrogen or on estrogen-independent, Tamoxifen-resistant (yet still ER&#x003b1;-positive) breast cancer cells.</p><p>Though its relevance to breast cancer is still emerging, ERR&#x003b2; has recently been identified as a highly expressed gene in epithelial cells present in human breast milk [<xref rid="r91" ref-type="bibr">Twigger et al., 2015</xref>], particularly early in lactation. Interestingly, principal component analysis of differentially-expressed genes identified in this study show that ERR&#x003b2; variance is opposite to that of KLF4, which it can replace in mouse iPSC reprogramming [<xref rid="r27" ref-type="bibr">Feng et al., 2009</xref>]. The contribution of ERR&#x003b2; to lactation requires further study, particularly given that lactating mammary tissue requires an intricate balance between epithelial cell self-renewal and differentiation.</p></sec><sec><title>Glioblastoma</title><p> GBM is the most common tumor of the brain, incurable and highly resistant to systemic chemotherapies. Surgery, radiation and adjuvant treatment with the alkylating agent temozolomide are the current standard of care, and result in a median survival of only ~14 months (reviewed in [<xref rid="r72" ref-type="bibr">Prados et al., 2015</xref>]). ESRRB is located at 14q24.3, a region frequently deleted in GBMs and lower grade astrocytic tumors [<xref rid="r24" ref-type="bibr">Dichamp et al., 2004</xref>; <xref rid="r26" ref-type="bibr">Felsberg et al., 2006</xref>; <xref rid="r41" ref-type="bibr">Hu et al., 2002</xref>], with Hu et al. showing 47.1% of GBMs in their study to have loss of heterozygosity (LOH) at 14q23-31. Using copy number data from REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) [<xref rid="r59" ref-type="bibr">Madhavan et al., 2009</xref>], now housed within the Georgetown Database of Cancer (GDOC) [<xref rid="r58" ref-type="bibr">Madhavan et al., 2011</xref>], we find that patients with ESRRB deletion have significantly worst survival (<xref ref-type="fig" rid="f2">Figure 2</xref>), supporting further mechanistic evaluation of ERR&#x003b2; in GBM.</p><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><title>ESRRB copy number and GBM survival.</title><p>Kaplan-Meier estimation was performed on &#x02018;all glioma&#x02019; Specimens in REMBRANDT using default parameters. Amplified (red) vs. deleted (green) p=0.007; amplified (red) vs. all (yellow) p=0.05; deleted (green) vs. all (yellow) p=0.02.</p></caption><graphic xlink:href="nrs-14-002-g2"/></fig><p>We have recently published that ERR&#x003b2;sf and ERR&#x003b2;2 differentially regulate cell cycle progression in GBM cell lines upon stimulation with DY131, and that this ligand has growth-inhibitory effects in GBM, but not nontransformed, cells [<xref rid="r38" ref-type="bibr">Heckler and Riggins, 2015</xref>; <xref rid="r97" ref-type="bibr">Vanacker and Maiorano, 2015</xref>]. Growth inhibition is the result of cell cycle arrest and, in cells lacking a functional p53, apoptosis. Intriguingly, the stage at which cell cycle arrest occurs in response to DY131 differs between cell line, and this is the direct result of which splice variant &#x02013; ERR&#x003b2;sf or ERR&#x003b2;2 &#x02013; is dominant. ERR&#x003b2;sf, as shown previously in prostate cancer models by [<xref rid="r112" ref-type="bibr">Yu et al., 2008</xref>], drives G1 arrest and the induction of p21, though we also observe senescence, which has not been previously reported. By contrast, ERR&#x003b2;2 is required for a G2/M arrest that we hypothesize is due to defective metaphase, given the persistence of Serine 10 phosphorylation on Histone H3. We also demonstrate that ERR&#x003b2;2 is a dominant-negative inhibitor of ERR&#x003b2;sf-dependent transcriptional activation of the p21 promoter. Our study was the first to identify a function for endogenous ERR&#x003b2;2 and define its dominant-inhibitory role. Key to this work was our discovery that two distinct monoclonal antibodies (H6707 and H6705, R&#x00026;D Systems) preferentially recognize endogenous ERR&#x003b2;2 and ERR&#x003b2;sf, respectively. It is not currently clear why these antibodies should prefer one splice variant to another, though ongoing studies have begun to elucidate the specific epitope(s) recognized. Rational development of ERR&#x003b2;2 and ERR&#x003b2;-&#x00394;10 splice variant-specific antibodies based on their divergent F domains should significantly improve the ability our group (and others) to study the expression and function of these splice variants at the protein level.</p></sec><sec><title>Pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL)</title><p> Hematologic malignancies are often characterized by genomic rearrangements, with some alteration of the transcription factor paired box 5 (PAX5) affecting ~40% of BCP ALL cases. It was recently reported that an unbalanced t(9;14) rearrangement is a recurrent event in this disease, leading to the production of a PAX5-ESRRB fusion gene [<xref rid="r61" ref-type="bibr">Marincevic-Zuniga et al., 2016</xref>; <xref rid="r65" ref-type="bibr">Nordlund et al., 2015</xref>]. The protein product of this fusion gene, which joins the amino terminal portion of PAX5 with the carboxy terminal portion of ERR&#x003b2;, is predicted to retain PAX5 DNA binding and protein/protein interaction activities and contain the full LBD of ERR&#x003b2;. The breakpoint occurs in intron 4 of ESRRB, which results in the loss of the first zinc finger of the DBD, demonstrated by [<xref rid="r112" ref-type="bibr">Yu et al., 2008</xref>] to abrogate receptor DNA binding. It is plausible that PAX5-ESRRB fusions may have alternatively spliced F domains analogous to ERR&#x003b2;2 and/or ERR&#x003b2;-&#x00394;10, but the reverse primer used to verify expression of the fusion transcript recognizes a sequence within exon 7, which is conserved in all splice variants. ESRRB expression is absent in ALLs lacking the fusion, implying that the PAX5 promoter is responsible for expression. In addition, ALLs positive for PAX5-ESRRB have a distinct DNA hypomethylation phenotype that is separable from those containing most other PAX5 fusions, and pathway analysis shows enrichment for genes in the Wnt/&#x003b2;-catenin pathway. This is intriguing, given that in mouse pluripotent cells ERR&#x003b2; is a target for Wnt pathway-mediated reprogramming [<xref rid="r62" ref-type="bibr">Martello et al., 2012</xref>]. Future functional studies will be required to specifically determine the contribution of the ERR&#x003b2; portion of the PAX5-ESRRB fusion to these events.</p></sec></sec><sec><title>Conclusions and future goals </title><p>The term &#x02018;renaissance&#x02019; can imply 1) renewed interest or growth in an area previously dormant, and 2) an individual possessing many talents. We think it fair to say that both apply to ERR&#x003b2; (<xref ref-type="fig" rid="f3">Figure 3</xref>). Key areas of future study and growth in this corner of the ONR field should include: deeper analysis of ERR&#x003b2; splice variant function and etiology, the latter being completely unexplored; development of ERR&#x003b2;-selective synthetic ligands that exploit Tyrosine 321 within the ligand-binding pocket; and a clearer understanding of the species-specific functions of this receptor, i.e., how ERR&#x003b2; behaves as a reprogramming factor in mice vs. a putative tumor suppressor in humans. Alternative splicing is a key source of functional diversity at the proteomic level, and it is likely that we have only just begun to scratch the surface of how this process impinges on the biologic function of ERR&#x003b2;, and likely other nuclear receptors. It is tempting to speculate that primate-restricted ERR&#x003b2; splice variants are responsible for tumor suppressor-like activity in humans, but the fact that we [<xref rid="r38" ref-type="bibr">Heckler and Riggins, 2015</xref>] and others [<xref rid="r86" ref-type="bibr">Tanida et al., 2015</xref>; <xref rid="r112" ref-type="bibr">Yu et al., 2008</xref>] find that ERR&#x003b2;sf is also growth limiting would suggest that the true explanation is not that simple. We have much to learn from the next 27 years of ERR&#x003b2;-focused research.</p><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><title>ERR&#x003b2; and its contributions to diverse biological processes.</title><p>Key functions of ERR&#x003b2; splice variants in rodents and primates are summarized.</p></caption><graphic xlink:href="nrs-14-002-g3"/></fig></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><label>Supplementary Material</label><caption><p>Supplementary Material</p></caption><media xlink:href="nrs-14-002-s1.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>Our goal in writing this review is to provide a comprehensive overview of the collective wisdom of investigators who have been or are currently studying ERR&#x003b2; in its many forms. We sincerely apologize if, in this effort, we have involuntarily omitted reference to a particular study. We further wish to thank all current and former members of the Riggins lab, and our colleagues within the Lombardi Comprehensive Cancer Center, for their insights and helpful suggestions, particularly Garrett Graham for critical reading of portions of the manuscript. Our work is generously supported by pilot funds from Partners in Research (partnersinresearch.gumc.georgetown.edu) awarded to RBR, developmental funds from the Lombardi Comprehensive Cancer Center (LCCC) Cancer Center Support Grant awarded to RBR (P30 CA051008; PI Dr. Louis M. Weiner), and R21 CA191444 awarded to RBR. Pre-doctoral fellowship funding is provided by the LCCC Tumor Biology Training Grant (DMT; T32 CA009686, PI Dr. Anna T. Riegel) and the Post Baccalaureate Training in Cancer Health Disparities Research Grant from Susan G. Komen for the Cure (AF; PBTDR1222836, PI Dr. Lucile Adams-Campbell). The content of this article is the sole responsibility of the authors and does not represent the official views of the National Cancer Institute, the National Institutes of Health, or Susan G. Komen for the Cure.</p></ack><fn-group><fn fn-type="conflict"><p>The authors have no potential conflicts of interest to disclose.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abad</surname><given-names>M. C.</given-names></name><name><surname>Askari</surname><given-names>H.</given-names></name><name><surname>O'Neill</surname><given-names>J.</given-names></name><name><surname>Klinger</surname><given-names>A. L.</given-names></name><name><surname>Milligan</surname><given-names>C.</given-names></name><name><surname>Lewandowski</surname><given-names>F.</given-names></name><name><surname>Springer</surname><given-names>B.</given-names></name><name><surname>Spurlino</surname><given-names>J.</given-names></name><name><surname>Rentzeperis</surname><given-names>D.</given-names></name></person-group> (<year>2008</year>). <article-title>Structural determination of estrogen-related receptor gamma in the presence of phenol derivative compounds.</article-title>
<source>J Steroid Biochem Mol Biol</source>
<volume>108</volume>, <fpage>44</fpage>-<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsbmb.2007.06.006</pub-id><?supplied-pmid 17964775?><pub-id pub-id-type="pmid">17964775</pub-id></mixed-citation></ref><ref id="r2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariazi</surname><given-names>E. A.</given-names></name><name><surname>Clark</surname><given-names>G. M.</given-names></name><name><surname>Mertz</surname><given-names>J. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.</article-title>
<source>Cancer Res</source>
<volume>62</volume>, <fpage>6510</fpage>-<lpage>6518</lpage>.<?supplied-pmid 12438245?><pub-id pub-id-type="pmid">12438245</pub-id></mixed-citation></ref><ref id="r3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariazi</surname><given-names>E. A.</given-names></name><name><surname>Jordan</surname><given-names>V. C.</given-names></name></person-group> (<year>2006</year>). <article-title>Estrogen-related receptors as emerging targets in cancer and metabolic disorders.</article-title>
<source>Curr Top Med Chem</source>
<volume>6</volume>, <fpage>203</fpage>-<lpage>215</lpage>. <pub-id pub-id-type="doi">10.2174/1568026610606030203</pub-id><?supplied-pmid 16515477?><pub-id pub-id-type="pmid">16515477</pub-id></mixed-citation></ref><ref id="r4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardet</surname><given-names>P. L.</given-names></name><name><surname>Obrecht-Pflumio</surname><given-names>S.</given-names></name><name><surname>Thisse</surname><given-names>C.</given-names></name><name><surname>Laudet</surname><given-names>V.</given-names></name><name><surname>Thisse</surname><given-names>B.</given-names></name><name><surname>Vanacker</surname><given-names>J. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Cloning and developmental expression of five estrogen-receptor related genes in the zebrafish.</article-title>
<source>Dev Genes Evol</source>
<volume>214</volume>, <fpage>240</fpage>-<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1007/s00427-004-0404-6</pub-id><?supplied-pmid 15088146?><pub-id pub-id-type="pmid">15088146</pub-id></mixed-citation></ref><ref id="r5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>J. B.</given-names></name><name><surname>Lagani&#x000e8;re</surname><given-names>J.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name></person-group> (<year>2006</year>). <article-title>A single nucleotide in an estrogen-related receptor alpha site can dictate mode of binding and peroxisome proliferator-activated receptor gamma coactivator 1alpha activation of target promoters.</article-title>
<source>Mol Endocrinol</source>
<volume>20</volume>, <fpage>302</fpage>-<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1210/me.2005-0313</pub-id><?supplied-pmid 16150865?><pub-id pub-id-type="pmid">16150865</pub-id></mixed-citation></ref><ref id="r6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Sa&#x000ef;d</surname><given-names>M.</given-names></name><name><surname>Ayedi</surname><given-names>L.</given-names></name><name><surname>Mnejja</surname><given-names>M.</given-names></name><name><surname>Hakim</surname><given-names>B.</given-names></name><name><surname>Khalfallah</surname><given-names>A.</given-names></name><name><surname>Charfeddine</surname><given-names>I.</given-names></name><name><surname>Khifagi</surname><given-names>C.</given-names></name><name><surname>Turki</surname><given-names>K.</given-names></name><name><surname>Ayadi</surname><given-names>H.</given-names></name><name><surname>Benzina</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>A novel missense mutation in the ESRRB gene causes DFNB35 hearing loss in a Tunisian family.</article-title>
<source>Eur J Med Genet</source>
<volume>54</volume>, <fpage>e535</fpage>-<lpage>541</lpage>.<?supplied-pmid 21802533?><pub-id pub-id-type="pmid">21802533</pub-id></mixed-citation></ref><ref id="r7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackshaw</surname><given-names>S.</given-names></name><name><surname>Fraioli</surname><given-names>R. E.</given-names></name><name><surname>Furukawa</surname><given-names>T.</given-names></name><name><surname>Cepko</surname><given-names>C. L.</given-names></name></person-group> (<year>2001</year>). <article-title>Comprehensive analysis of photoreceptor gene expression and the identification of candidate retinal disease genes.</article-title>
<source>Cell</source>
<volume>107</volume>, <fpage>579</fpage>-<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(01)00574-8</pub-id><?supplied-pmid 11733058?><pub-id pub-id-type="pmid">11733058</pub-id></mixed-citation></ref><ref id="r8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackshaw</surname><given-names>S.</given-names></name><name><surname>Harpavat</surname><given-names>S.</given-names></name><name><surname>Trimarchi</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Kuo</surname><given-names>W. P.</given-names></name><name><surname>Weber</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Fraioli</surname><given-names>R. E.</given-names></name><name><surname>Cho</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Genomic analysis of mouse retinal development.</article-title>
<source>PLoS Biol</source>
<volume>2</volume>, e<fpage>247</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0020247</pub-id><?supplied-pmid 15226823?><pub-id pub-id-type="pmid">15226823</pub-id></mixed-citation></ref><ref id="r9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombail</surname><given-names>V.</given-names></name><name><surname>Collins</surname><given-names>F.</given-names></name><name><surname>Brown</surname><given-names>P.</given-names></name><name><surname>Saunders</surname><given-names>P. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Modulation of ER alpha transcriptional activity by the orphan nuclear receptor ERR beta and evidence for differential effects of long- and short-form splice variants.</article-title>
<source>Mol Cell Endocrinol</source>
<volume>314</volume>, <fpage>53</fpage>-<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2009.09.007</pub-id><?supplied-pmid 19755138?><pub-id pub-id-type="pmid">19755138</pub-id></mixed-citation></ref><ref id="r10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bombail</surname><given-names>V.</given-names></name><name><surname>MacPherson</surname><given-names>S.</given-names></name><name><surname>Critchley</surname><given-names>H. O.</given-names></name><name><surname>Saunders</surname><given-names>P. T.</given-names></name></person-group> (<year>2008</year>). <article-title>Estrogen receptor related beta is expressed in human endometrium throughout the normal menstrual cycle.</article-title>
<source>Hum Reprod</source>
<volume>23</volume>, <fpage>2782</fpage>-<lpage>2790</lpage>. <pub-id pub-id-type="doi">10.1093/humrep/den298</pub-id><?supplied-pmid 18775884?><pub-id pub-id-type="pmid">18775884</pub-id></mixed-citation></ref><ref id="r11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byerly</surname><given-names>M. S.</given-names></name><name><surname>Al Salayta</surname><given-names>M.</given-names></name><name><surname>Swanson</surname><given-names>R. D.</given-names></name><name><surname>Kwon</surname><given-names>K.</given-names></name><name><surname>Peterson</surname><given-names>J. M.</given-names></name><name><surname>Wei</surname><given-names>Z.</given-names></name><name><surname>Aja</surname><given-names>S.</given-names></name><name><surname>Moran</surname><given-names>T. H.</given-names></name><name><surname>Blackshaw</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G. W.</given-names></name></person-group> (<year>2013</year><comment>a</comment>). <article-title>Estrogen-related receptor &#x003b2; deletion modulates whole-body energy balance via estrogen-related receptor &#x003b3; and attenuates neuropeptide Y gene expression.</article-title>
<source>Eur J Neurosci</source>. <volume>37</volume>, <fpage>1033</fpage>-<lpage>1047</lpage>. <pub-id pub-id-type="doi">10.1111/ejn.12122</pub-id><?supplied-pmid 23360481?><pub-id pub-id-type="pmid">23360481</pub-id></mixed-citation></ref><ref id="r12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byerly</surname><given-names>M. S.</given-names></name><name><surname>Swanson</surname><given-names>R. D.</given-names></name><name><surname>Wong</surname><given-names>G. W.</given-names></name><name><surname>Blackshaw</surname><given-names>S.</given-names></name></person-group> (<year>2013</year><comment>b</comment>). <article-title>Estrogen-related receptor &#x003b2; deficiency alters body composition and response to restraint stress.</article-title>
<source>BMC Physiol</source>
<volume>13</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6793-13-10</pub-id><?supplied-pmid 24053666?><pub-id pub-id-type="pmid">24053666</pub-id></mixed-citation></ref><ref id="r13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castet</surname><given-names>A.</given-names></name><name><surname>Herledan</surname><given-names>A.</given-names></name><name><surname>Bonnet</surname><given-names>S.</given-names></name><name><surname>Jalaguier</surname><given-names>S.</given-names></name><name><surname>Vanacker</surname><given-names>J. M.</given-names></name><name><surname>Cavailles</surname><given-names>V.</given-names></name></person-group> (<year>2006</year>). <article-title>Receptor-Interacting Protein 140 Differentially Regulates Estrogen Receptor-Related Receptor Transactivation Depending on Target Genes.</article-title>
<source>Molecular Endocrinology</source>
<volume>20</volume>, <fpage>1035</fpage>-<lpage>1047</lpage>. <pub-id pub-id-type="doi">10.1210/me.2005-0227</pub-id><?supplied-pmid 16439465?><pub-id pub-id-type="pmid">16439465</pub-id></mixed-citation></ref><ref id="r14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>E. Y.</given-names></name><name><surname>Collins</surname><given-names>J. L.</given-names></name><name><surname>Gaillard</surname><given-names>S.</given-names></name><name><surname>Miller</surname><given-names>A. B.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Orband-Miller</surname><given-names>L. A.</given-names></name><name><surname>Nolte</surname><given-names>R. T.</given-names></name><name><surname>McDonnell</surname><given-names>D. P.</given-names></name><name><surname>Willson</surname><given-names>T. M.</given-names></name><name><surname>Zuercher</surname><given-names>W. J.</given-names></name></person-group> (<year>2006</year>). <article-title>Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma.</article-title>
<source>Bioorg Med Chem Lett</source>
<volume>16</volume>, <fpage>821</fpage>-<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.11.030</pub-id><?supplied-pmid 16307879?><pub-id pub-id-type="pmid">16307879</pub-id></mixed-citation></ref><ref id="r15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>McDonald</surname><given-names>T.</given-names></name><name><surname>Davidoff</surname><given-names>M. J.</given-names></name><name><surname>Bailey</surname><given-names>W.</given-names></name><name><surname>Bai</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Caskey</surname><given-names>C. T.</given-names></name></person-group> (<year>1999</year>). <article-title>Identification of two hERR2-related novel nuclear receptors utilizing bioinformatics and inverse PCR.</article-title>
<source>Gene</source>
<volume>228</volume>, <fpage>101</fpage>-<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1119(98)00619-2</pub-id><?supplied-pmid 10072763?><pub-id pub-id-type="pmid">10072763</pub-id></mixed-citation></ref><ref id="r16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Nathans</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Estrogen-related receptor beta/NR3B2 controls epithelial cell fate and endolymph production by the stria vascularis.</article-title>
<source>Dev Cell</source>
<volume>13</volume>, <fpage>325</fpage>-<lpage>337</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2007.07.011</pub-id><?supplied-pmid 17765677?><pub-id pub-id-type="pmid">17765677</pub-id></mixed-citation></ref><ref id="r17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Yuan</surname><given-names>P.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Huss</surname><given-names>M.</given-names></name><name><surname>Vega</surname><given-names>V. B.</given-names></name><name><surname>Wong</surname><given-names>E.</given-names></name><name><surname>Orlov</surname><given-names>Y. L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Integration of external signaling pathways with the core transcriptional network in embryonic stem cells.</article-title>
<source>Cell</source>
<volume>133</volume>, <fpage>1106</fpage>-<lpage>1117</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.04.043</pub-id><?supplied-pmid 18555785?><pub-id pub-id-type="pmid">18555785</pub-id></mixed-citation></ref><ref id="r18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>C. P.</given-names></name><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>K. B.</given-names></name><name><surname>Chan</surname><given-names>L. W.</given-names></name><name><surname>Lai</surname><given-names>F. M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Suetsugi</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>F. L.</given-names></name></person-group> (<year>2005</year>). <article-title>Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues 1 7347.</article-title>
<source>J. Clin. Endocrinol. Metab.</source>
<volume>90</volume>, <fpage>1830</fpage>-<lpage>1844</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2004-1421</pub-id><?supplied-pmid 15598686?><pub-id pub-id-type="pmid">15598686</pub-id></mixed-citation></ref><ref id="r19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccia</surname><given-names>A.</given-names></name><name><surname>Elledge</surname><given-names>S. J.</given-names></name></person-group> (<year>2010</year>). <article-title>The DNA damage response: making it safe to play with knives.</article-title>
<source>Mol Cell</source>
<volume>40</volume>, <fpage>179</fpage>-<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2010.09.019</pub-id><?supplied-pmid 20965415?><pub-id pub-id-type="pmid">20965415</pub-id></mixed-citation></ref><ref id="r20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collin</surname><given-names>R. W.</given-names></name><name><surname>Kalay</surname><given-names>E.</given-names></name><name><surname>Tariq</surname><given-names>M.</given-names></name><name><surname>Peters</surname><given-names>T.</given-names></name><name><surname>van der Zwaag</surname><given-names>B.</given-names></name><name><surname>Venselaar</surname><given-names>H.</given-names></name><name><surname>Oostrik</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Ahmed</surname><given-names>Z. M.</given-names></name><name><surname>Caylan</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Mutations of ESRRB encoding estrogen-related receptor beta cause autosomal-recessive nonsyndromic hearing impairment DFNB35.</article-title>
<source>Am J Hum Genet</source>
<volume>82</volume>, <fpage>125</fpage>-<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2007.09.008</pub-id><?supplied-pmid 18179891?><pub-id pub-id-type="pmid">18179891</pub-id></mixed-citation></ref><ref id="r21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coward</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>D.</given-names></name><name><surname>Hull</surname><given-names>M. V.</given-names></name><name><surname>Lehmann</surname><given-names>J. M.</given-names></name></person-group> (<year>2001</year>). <article-title>4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>98</volume>, <fpage>8880</fpage>-<lpage>8884</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.151244398</pub-id><?supplied-pmid 11447273?><pub-id pub-id-type="pmid">11447273</pub-id></mixed-citation></ref><ref id="r22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darimont</surname><given-names>B. D.</given-names></name><name><surname>Wagner</surname><given-names>R. L.</given-names></name><name><surname>Apriletti</surname><given-names>J. W.</given-names></name><name><surname>Stallcup</surname><given-names>M. R.</given-names></name><name><surname>Kushner</surname><given-names>P. J.</given-names></name><name><surname>Baxter</surname><given-names>J. D.</given-names></name><name><surname>Fletterick</surname><given-names>R. J.</given-names></name><name><surname>Yamamoto</surname><given-names>K. R.</given-names></name></person-group> (<year>1998</year>). <article-title>Structure and specificity of nuclear receptor-coactivator interactions.</article-title>
<source>Genes Dev</source>
<volume>12</volume>, <fpage>3343</fpage>-<lpage>3356</lpage>. <pub-id pub-id-type="doi">10.1101/gad.12.21.3343</pub-id><?supplied-pmid 9808622?><pub-id pub-id-type="pmid">9808622</pub-id></mixed-citation></ref><ref id="r23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Micco</surname><given-names>S.</given-names></name><name><surname>Renga</surname><given-names>B.</given-names></name><name><surname>Carino</surname><given-names>A.</given-names></name><name><surname>D'Auria</surname><given-names>M. V.</given-names></name><name><surname>Zampella</surname><given-names>A.</given-names></name><name><surname>Riccio</surname><given-names>R.</given-names></name><name><surname>Fiorucci</surname><given-names>S.</given-names></name><name><surname>Bifulco</surname><given-names>G.</given-names></name></person-group> (<year>2014</year>). <article-title>Structural insights into Estrogen Related Receptor-&#x003b2; modulation: 4-Methylenesterols from Theonella swinhoei sponge as the first example of marine natural antagonists.</article-title>
<source>Steroids</source>
<volume>80</volume>, <fpage>51</fpage>-<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.steroids.2013.11.017</pub-id><?supplied-pmid 24315836?><pub-id pub-id-type="pmid">24315836</pub-id></mixed-citation></ref><ref id="r24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dichamp</surname><given-names>C.</given-names></name><name><surname>Taillibert</surname><given-names>S.</given-names></name><name><surname>Aguirre-Cruz</surname><given-names>L.</given-names></name><name><surname>Lejeune</surname><given-names>J.</given-names></name><name><surname>Marie</surname><given-names>Y.</given-names></name><name><surname>Kujas</surname><given-names>M.</given-names></name><name><surname>Delattre</surname><given-names>J. Y.</given-names></name><name><surname>Hoang-Xuan</surname><given-names>K.</given-names></name><name><surname>Sanson</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Loss of 14q chromosome in oligodendroglial and astrocytic tumors.</article-title>
<source>J Neurooncol</source>
<volume>67</volume>, <fpage>281</fpage>-<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1023/B:NEON.0000024218.68120.8d</pub-id><?supplied-pmid 15164983?><pub-id pub-id-type="pmid">15164983</pub-id></mixed-citation></ref><ref id="r25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelen</surname><given-names>E.</given-names></name><name><surname>Brandsma</surname><given-names>J. H.</given-names></name><name><surname>Moen</surname><given-names>M. J.</given-names></name><name><surname>Signorile</surname><given-names>L.</given-names></name><name><surname>Dekkers</surname><given-names>D. H.</given-names></name><name><surname>Demmers</surname><given-names>J.</given-names></name><name><surname>Kockx</surname><given-names>C. E.</given-names></name><name><surname>Ozg&#x000fc;r</surname><given-names>Z.</given-names></name><name><surname>van IJcken</surname><given-names>W. F.</given-names></name><name><surname>van den Berg</surname><given-names>D. L.</given-names></name><name><surname>Poot</surname><given-names>R. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Proteins that bind regulatory regions identified by histone modification chromatin immunoprecipitations and mass spectrometry.</article-title>
<source>Nat Commun</source>
<volume>6</volume>, <fpage>7155</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8155</pub-id><?supplied-pmid 25990348?><pub-id pub-id-type="pmid">25990348</pub-id></mixed-citation></ref><ref id="r26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felsberg</surname><given-names>J.</given-names></name><name><surname>Yan</surname><given-names>P. S.</given-names></name><name><surname>Huang</surname><given-names>T. H.</given-names></name><name><surname>Milde</surname><given-names>U.</given-names></name><name><surname>Schramm</surname><given-names>J.</given-names></name><name><surname>Wiestler</surname><given-names>O. D.</given-names></name><name><surname>Reifenberger</surname><given-names>G.</given-names></name><name><surname>Pietsch</surname><given-names>T.</given-names></name><name><surname>Waha</surname><given-names>A.</given-names></name></person-group> (<year>2006</year>). <article-title>DNA methylation and allelic losses on chromosome arm 14q in oligodendroglial tumours.</article-title>
<source>Neuropathol Appl Neurobiol</source>
<volume>32</volume>, <fpage>517</fpage>-<lpage>524</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2990.2006.00759.x</pub-id><?supplied-pmid 16972885?><pub-id pub-id-type="pmid">16972885</pub-id></mixed-citation></ref><ref id="r27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Kraus</surname><given-names>P.</given-names></name><name><surname>Ng</surname><given-names>J. H.</given-names></name><name><surname>Heng</surname><given-names>J. C.</given-names></name><name><surname>Chan</surname><given-names>Y. S.</given-names></name><name><surname>Yaw</surname><given-names>L. P.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Loh</surname><given-names>Y. H.</given-names></name><name><surname>Han</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb.</article-title>
<source>Nat Cell Biol</source>
<volume>11</volume>, <fpage>197</fpage>-<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1038/ncb1827</pub-id><?supplied-pmid 19136965?><pub-id pub-id-type="pmid">19136965</pub-id></mixed-citation></ref><ref id="r28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festuccia</surname><given-names>N.</given-names></name><name><surname>Osorno</surname><given-names>R.</given-names></name><name><surname>Halbritter</surname><given-names>F.</given-names></name><name><surname>Karwacki-Neisius</surname><given-names>V.</given-names></name><name><surname>Navarro</surname><given-names>P.</given-names></name><name><surname>Colby</surname><given-names>D.</given-names></name><name><surname>Wong</surname><given-names>F.</given-names></name><name><surname>Yates</surname><given-names>A.</given-names></name><name><surname>Tomlinson</surname><given-names>S. R.</given-names></name><name><surname>Chambers</surname><given-names>I.</given-names></name></person-group> (<year>2012</year>). <article-title>Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells.</article-title>
<source>Cell Stem Cell</source>
<volume>11</volume>, <fpage>477</fpage>-<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2012.08.002</pub-id><?supplied-pmid 23040477?><pub-id pub-id-type="pmid">23040477</pub-id></mixed-citation></ref><ref id="r29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujimura</surname><given-names>T.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Urano</surname><given-names>T.</given-names></name><name><surname>Ijichi</surname><given-names>N.</given-names></name><name><surname>Ikeda</surname><given-names>K.</given-names></name><name><surname>Kumagai</surname><given-names>J.</given-names></name><name><surname>Murata</surname><given-names>T.</given-names></name><name><surname>Takayama</surname><given-names>K.</given-names></name><name><surname>Horie-Inoue</surname><given-names>K.</given-names></name><name><surname>Ouchi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Differential expression of estrogen-related receptors beta and gamma (ERRbeta and ERRgamma) and their clinical significance in human prostate cancer.</article-title>
<source>Cancer Sci</source>
<volume>101</volume>, <fpage>646</fpage>-<lpage>651</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01451.x</pub-id><?supplied-pmid 20128821?><pub-id pub-id-type="pmid">20128821</pub-id></mixed-citation></ref><ref id="r30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallastegui</surname><given-names>N.</given-names></name><name><surname>Mackinnon</surname><given-names>J. A.</given-names></name><name><surname>Fletterick</surname><given-names>R. J.</given-names></name><name><surname>Est&#x000e9;banez-Perpi&#x000f1;&#x000e1;</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Advances in our structural understanding of orphan nuclear receptors.</article-title>
<source>Trends Biochem Sci</source>
<volume>40</volume>, <fpage>25</fpage>-<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2014.11.002</pub-id><?supplied-pmid 25499868?><pub-id pub-id-type="pmid">25499868</pub-id></mixed-citation></ref><ref id="r31"><mixed-citation publication-type="other">Garattini, E., Bolis, M., Gianni, M., Paroni, G., Fratelli, M.and Terao, M. (2016). Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer. <italic>Oncotarget,</italic>
<bold>5</bold>.</mixed-citation></ref><ref id="r32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gearhart</surname><given-names>M. D.</given-names></name><name><surname>Holmbeck</surname><given-names>S.</given-names></name><name><surname>Evans</surname><given-names>R.</given-names></name><name><surname>Dyson</surname><given-names>H.</given-names></name><name><surname>Wright</surname><given-names>P.</given-names></name></person-group> (<year>2003</year>). <article-title>Monomeric complex of human orphan estrogen related receptor-2 with DNA: a pseudo-dimer interface mediates extended half-site recognition.</article-title>
<source>J Mol Biol</source>
<volume>327</volume>, <fpage>819</fpage>-<lpage>832</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(03)00183-9</pub-id><?supplied-pmid 12654265?><pub-id pub-id-type="pmid">12654265</pub-id></mixed-citation></ref><ref id="r33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gearhart</surname><given-names>M. D.</given-names></name><name><surname>Dickinson</surname><given-names>L.</given-names></name><name><surname>Ehley</surname><given-names>J.</given-names></name><name><surname>Melander</surname><given-names>C.</given-names></name><name><surname>Dervan</surname><given-names>P. B.</given-names></name><name><surname>Wright</surname><given-names>P. E.</given-names></name><name><surname>Gottesfeld</surname><given-names>J. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor alpha with minor groove binding polyamides.</article-title>
<source>Biochemistry</source>
<volume>44</volume>, <fpage>4196</fpage>-<lpage>4203</lpage>. <pub-id pub-id-type="doi">10.1021/bi047872o</pub-id><?supplied-pmid 15766247?><pub-id pub-id-type="pmid">15766247</pub-id></mixed-citation></ref><ref id="r34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Segui</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>R. M.</given-names></name></person-group> (<year>1988</year>). <article-title>Identification of a new class of steroid hormone receptors.</article-title>
<source>Nature</source>
<volume>331</volume>, <fpage>91</fpage>-<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/331091a0</pub-id><?supplied-pmid 3267207?><pub-id pub-id-type="pmid">3267207</pub-id></mixed-citation></ref><ref id="r35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greschik</surname><given-names>H.</given-names></name><name><surname>Flaig</surname><given-names>R.</given-names></name><name><surname>Renaud</surname><given-names>J. P.</given-names></name><name><surname>Moras</surname><given-names>D.</given-names></name></person-group> (<year>2004</year>). <article-title>Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.</article-title>
<source>J. Biol. Chem.</source>
<volume>279</volume>, <fpage>33639</fpage>-<lpage>33646</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M402195200</pub-id><?supplied-pmid 15161930?><pub-id pub-id-type="pmid">15161930</pub-id></mixed-citation></ref><ref id="r36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greschik</surname><given-names>H.</given-names></name><name><surname>Wurtz</surname><given-names>J. M.</given-names></name><name><surname>Sanglier</surname><given-names>S.</given-names></name><name><surname>Bourguet</surname><given-names>W.</given-names></name><name><surname>van Dorsselaer</surname><given-names>A.</given-names></name><name><surname>Moras</surname><given-names>D.</given-names></name><name><surname>Renaud</surname><given-names>J. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3.</article-title>
<source>Mol. Cell</source>
<volume>9</volume>, <fpage>303</fpage>-<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1016/S1097-2765(02)00444-6</pub-id><?supplied-pmid 11864604?><pub-id pub-id-type="pmid">11864604</pub-id></mixed-citation></ref><ref id="r37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>R. M.</given-names></name><name><surname>Waring</surname><given-names>R. H.</given-names></name></person-group> (<year>2012</year>). <article-title>Diethylstilboestrol--a long-term legacy.</article-title>
<source>Maturitas</source>
<volume>72</volume>, <fpage>108</fpage>-<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.maturitas.2012.03.002</pub-id><?supplied-pmid 22464649?><pub-id pub-id-type="pmid">22464649</pub-id></mixed-citation></ref><ref id="r38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckler</surname><given-names>M. M.</given-names></name><name><surname>Riggins</surname><given-names>R. B.</given-names></name></person-group> (<year>2015</year>). <article-title>ERR&#x003b2; splice variants differentially regulate cell cycle progression.</article-title>
<source>Cell Cycle</source>
<volume>14</volume>, <fpage>31</fpage>-<lpage>45</lpage>. <pub-id pub-id-type="doi">10.4161/15384101.2014.972886</pub-id><?supplied-pmid 25496115?><pub-id pub-id-type="pmid">25496115</pub-id></mixed-citation></ref><ref id="r39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heery</surname><given-names>D. M.</given-names></name><name><surname>Kalkhoven</surname><given-names>E.</given-names></name><name><surname>Hoare</surname><given-names>S.</given-names></name><name><surname>Parker</surname><given-names>M. G.</given-names></name></person-group> (<year>1997</year>). <article-title>A signature motif in transcriptional co-activators mediates binding to nuclear receptors.</article-title>
<source>Nature</source>
<volume>387</volume>, <fpage>733</fpage>-<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1038/42750</pub-id><?supplied-pmid 9192902?><pub-id pub-id-type="pmid">9192902</pub-id></mixed-citation></ref><ref id="r40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilakivi-Clarke</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters.</article-title>
<source>Breast Cancer Res</source>
<volume>16</volume>, <fpage>208</fpage>. <pub-id pub-id-type="doi">10.1186/bcr3649</pub-id><?supplied-pmid 25032259?><pub-id pub-id-type="pmid">25032259</pub-id></mixed-citation></ref><ref id="r41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Pang</surname><given-names>J. C.</given-names></name><name><surname>Tong</surname><given-names>C. Y.</given-names></name><name><surname>Lau</surname><given-names>B.</given-names></name><name><surname>Yin</surname><given-names>X. L.</given-names></name><name><surname>Poon</surname><given-names>W. S.</given-names></name><name><surname>Jiang</surname><given-names>C. C.</given-names></name><name><surname>Zhou</surname><given-names>L. F.</given-names></name><name><surname>Ng</surname><given-names>H. K.</given-names></name></person-group> (<year>2002</year>). <article-title>High-resolution genome-wide allelotype analysis identifies loss of chromosome 14q as a recurrent genetic alteration in astrocytic tumours.</article-title>
<source>Br J Cancer</source>
<volume>87</volume>, <fpage>218</fpage>-<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6600430</pub-id><?supplied-pmid 12107846?><pub-id pub-id-type="pmid">12107846</pub-id></mixed-citation></ref><ref id="r42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>Y.</given-names></name><name><surname>Lala</surname><given-names>D. S.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Moisan</surname><given-names>M. P.</given-names></name><name><surname>Parker</surname><given-names>K. L.</given-names></name></person-group> (<year>1993</year>). <article-title>Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid hydroxylase gene expression.</article-title>
<source>Mol Endocrinol</source>
<volume>7</volume>, <fpage>852</fpage>-<lpage>860</lpage>.<?supplied-pmid 8413309?><pub-id pub-id-type="pmid">8413309</pub-id></mixed-citation></ref><ref id="r43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivanova</surname><given-names>N.</given-names></name><name><surname>Dobrin</surname><given-names>R.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Kotenko</surname><given-names>I.</given-names></name><name><surname>Levorse</surname><given-names>J.</given-names></name><name><surname>DeCoste</surname><given-names>C.</given-names></name><name><surname>Schafer</surname><given-names>X.</given-names></name><name><surname>Lun</surname><given-names>Y.</given-names></name><name><surname>Lemischka</surname><given-names>I. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Dissecting self-renewal in stem cells with RNA interference.</article-title>
<source>Nature</source>
<volume>442</volume>, <fpage>533</fpage>-<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1038/nature04915</pub-id><?supplied-pmid 16767105?><pub-id pub-id-type="pmid">16767105</pub-id></mixed-citation></ref><ref id="r44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katano</surname><given-names>M.</given-names></name><name><surname>Ema</surname><given-names>M.</given-names></name><name><surname>Nakachi</surname><given-names>Y.</given-names></name><name><surname>Mizuno</surname><given-names>Y.</given-names></name><name><surname>Hirasaki</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Ueda</surname><given-names>A.</given-names></name><name><surname>Nishimoto</surname><given-names>M.</given-names></name><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Okazaki</surname><given-names>Y.</given-names></name><name><surname>Okuda</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Forced expression of Nanog or Esrrb preserves the ESC status in the absence of nucleostemin expression.</article-title>
<source>Stem Cells</source>
<volume>33</volume>, <fpage>1089</fpage>-<lpage>1101</lpage>.<?supplied-pmid 25522312?><pub-id pub-id-type="pmid">25522312</pub-id></mixed-citation></ref><ref id="r45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>L. A.</given-names></name><name><surname>Sternberg</surname><given-names>M. J.</given-names></name></person-group> (<year>2009</year>). <article-title>Protein structure prediction on the Web: a case study using the Phyre server.</article-title>
<source>Nat Protoc</source>
<volume>4</volume>, <fpage>363</fpage>-<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2009.2</pub-id><?supplied-pmid 19247286?><pub-id pub-id-type="pmid">19247286</pub-id></mixed-citation></ref><ref id="r46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kues</surname><given-names>W. A.</given-names></name><name><surname>Herrmann</surname><given-names>D.</given-names></name><name><surname>Barg-Kues</surname><given-names>B.</given-names></name><name><surname>Haridoss</surname><given-names>S.</given-names></name><name><surname>Nowak-Imialek</surname><given-names>M.</given-names></name><name><surname>Buchholz</surname><given-names>T.</given-names></name><name><surname>Streeck</surname><given-names>M.</given-names></name><name><surname>Grebe</surname><given-names>A.</given-names></name><name><surname>Grabundzija</surname><given-names>I.</given-names></name><name><surname>Merkert</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells.</article-title>
<source>Stem Cells Dev</source>
<volume>22</volume>, <fpage>124</fpage>-<lpage>135</lpage>.<?supplied-pmid 22989381?><pub-id pub-id-type="pmid">22989381</pub-id></mixed-citation></ref><ref id="r47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Mendelson</surname><given-names>C. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Estrogen-related receptor gamma (ERRgamma) mediates oxygen-dependent induction of aromatase (CYP19) gene expression during human trophoblast differentiation.</article-title>
<source>Mol Endocrinol</source>
<volume>25</volume>, <fpage>1513</fpage>-<lpage>1526</lpage>. <pub-id pub-id-type="doi">10.1210/me.2011-1012</pub-id><?supplied-pmid 21757507?><pub-id pub-id-type="pmid">21757507</pub-id></mixed-citation></ref><ref id="r48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latos</surname><given-names>P. A.</given-names></name><name><surname>Goncalves</surname><given-names>A.</given-names></name><name><surname>Oxley</surname><given-names>D.</given-names></name><name><surname>Mohammed</surname><given-names>H.</given-names></name><name><surname>Turro</surname><given-names>E.</given-names></name><name><surname>Hemberger</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Fgf and Esrrb integrate epigenetic and transcriptional networks that regulate self-renewal of trophoblast stem cells.</article-title>
<source>Nat Commun</source>
<volume>6</volume>, <fpage>7776</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms8776</pub-id><?supplied-pmid 26206133?><pub-id pub-id-type="pmid">26206133</pub-id></mixed-citation></ref><ref id="r49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lein</surname><given-names>E. S.</given-names></name><name><surname>Hawrylycz</surname><given-names>M. J.</given-names></name><name><surname>Ao</surname><given-names>N.</given-names></name><name><surname>Ayres</surname><given-names>M.</given-names></name><name><surname>Bensinger</surname><given-names>A.</given-names></name><name><surname>Bernard</surname><given-names>A.</given-names></name><name><surname>Boe</surname><given-names>A. F.</given-names></name><name><surname>Boguski</surname><given-names>M. S.</given-names></name><name><surname>Brockway</surname><given-names>K. S.</given-names></name><name><surname>Byrnes</surname><given-names>E. J.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Genome-wide atlas of gene expression in the adult mouse brain.</article-title>
<source>Nature</source>
<volume>445</volume>, <fpage>168</fpage>-<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1038/nature05453</pub-id><?supplied-pmid 17151600?><pub-id pub-id-type="pmid">17151600</pub-id></mixed-citation></ref><ref id="r50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Matsushima</surname><given-names>A.</given-names></name><name><surname>Shimohigashi</surname><given-names>M.</given-names></name><name><surname>Shimohigashi</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>A Characteristic Back Support Structure in the Bisphenol A-Binding Pocket in the Human Nuclear Receptor ERR&#x003b3;.</article-title>
<source>PLoS One</source>
<volume>9</volume>, <fpage>e101252</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0101252</pub-id><?supplied-pmid 24978476?><pub-id pub-id-type="pmid">24978476</pub-id></mixed-citation></ref><ref id="r51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>Y. H.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Chew</surname><given-names>J. L.</given-names></name><name><surname>Vega</surname><given-names>V. B.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Bourque</surname><given-names>G.</given-names></name><name><surname>George</surname><given-names>J.</given-names></name><name><surname>Leong</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells.</article-title>
<source>Nat Genet</source>
<volume>38</volume>, <fpage>431</fpage>-<lpage>440</lpage>.<?supplied-pmid 16518401?><pub-id pub-id-type="pmid">16518401</pub-id></mixed-citation></ref><ref id="r52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D.</given-names></name><name><surname>Kiriyama</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>K.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name></person-group> (<year>2001</year>). <article-title>Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors.</article-title>
<source>Cancer Res</source>
<volume>61</volume>, <fpage>6755</fpage>-<lpage>6761</lpage>.<?supplied-pmid 11559547?><pub-id pub-id-type="pmid">11559547</pub-id></mixed-citation></ref><ref id="r53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Lubahn</surname><given-names>D. B.</given-names></name></person-group> (<year>2015</year><comment>a</comment>). <article-title>Genes targeted by the Hedgehog-signaling pathway can be regulated by Estrogen related receptor &#x003b2;.</article-title>
<source>BMC Mol Biol</source>
<volume>16</volume>, <fpage>19</fpage>. <pub-id pub-id-type="doi">10.1186/s12867-015-0047-3</pub-id><?supplied-pmid 26597826?><pub-id pub-id-type="pmid">26597826</pub-id></mixed-citation></ref><ref id="r54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>J.</given-names></name><name><surname>Lubahn</surname><given-names>D. B.</given-names></name></person-group> (<year>2015</year><comment>b</comment>). <article-title>Messenger RNA profile analysis deciphers new Esrrb responsive genes in prostate cancer cells.</article-title>
<source>BMC Mol Biol</source>
<volume>16</volume>, <fpage>21</fpage>. <pub-id pub-id-type="doi">10.1186/s12867-015-0049-1</pub-id><?supplied-pmid 26627478?><pub-id pub-id-type="pmid">26627478</pub-id></mixed-citation></ref><ref id="r55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luijendijk</surname><given-names>M. W.</given-names></name><name><surname>van de Pol</surname><given-names>T. J.</given-names></name><name><surname>van Duijnhoven</surname><given-names>G.</given-names></name><name><surname>den Hollander</surname><given-names>A. I.</given-names></name><name><surname>ten Caat</surname><given-names>J.</given-names></name><name><surname>van Limpt</surname><given-names>V.</given-names></name><name><surname>Brunner</surname><given-names>H. G.</given-names></name><name><surname>Kremer</surname><given-names>H.</given-names></name><name><surname>Cremers</surname><given-names>F. P.</given-names></name></person-group> (<year>2003</year>). <article-title>Cloning, characterization, and mRNA expression analysis of novel human fetal cochlear cDNAs.</article-title>
<source>Genomics</source>
<volume>82</volume>, <fpage>480</fpage>-<lpage>490</lpage>. <pub-id pub-id-type="doi">10.1016/S0888-7543(03)00150-2</pub-id><?supplied-pmid 13679028?><pub-id pub-id-type="pmid">13679028</pub-id></mixed-citation></ref><ref id="r56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Sladek</surname><given-names>R.</given-names></name><name><surname>Bader</surname><given-names>J. A.</given-names></name><name><surname>Matthyssen</surname><given-names>A.</given-names></name><name><surname>Rossant</surname><given-names>J.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name></person-group> (<year>1997</year>). <article-title>Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta.</article-title>
<source>Nature</source>
<volume>388</volume>, <fpage>778</fpage>-<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1038/42022</pub-id><?supplied-pmid 9285590?><pub-id pub-id-type="pmid">9285590</pub-id></mixed-citation></ref><ref id="r57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydon</surname><given-names>J. P.</given-names></name><name><surname>Power</surname><given-names>R. F.</given-names></name><name><surname>Conneely</surname><given-names>O. M.</given-names></name></person-group> (<year>1992</year>). <article-title>Differential modes of activation define orphan subclasses within the steroid/thyroid receptor superfamily.</article-title>
<source>Gene Expr</source>
<volume>2</volume>, <fpage>273</fpage>-<lpage>283</lpage>.<?supplied-pmid 1450665?><pub-id pub-id-type="pmid">1450665</pub-id></mixed-citation></ref><ref id="r58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhavan</surname><given-names>S.</given-names></name><name><surname>Gusev</surname><given-names>Y.</given-names></name><name><surname>Harris</surname><given-names>M.</given-names></name><name><surname>Tanenbaum</surname><given-names>D. M.</given-names></name><name><surname>Gauba</surname><given-names>R.</given-names></name><name><surname>Bhuvaneshwar</surname><given-names>K.</given-names></name><name><surname>Shinohara</surname><given-names>A.</given-names></name><name><surname>Rosso</surname><given-names>K.</given-names></name><name><surname>Carabet</surname><given-names>L. A.</given-names></name><name><surname>Song</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>G-DOC: A Systems Medicine Platform for Personalized Oncology.</article-title>
<source>Neoplasia</source>
<volume>13</volume>, <fpage>771</fpage>-<lpage>783</lpage>. <pub-id pub-id-type="doi">10.1593/neo.11806</pub-id><?supplied-pmid 21969811?><pub-id pub-id-type="pmid">21969811</pub-id></mixed-citation></ref><ref id="r59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madhavan</surname><given-names>S.</given-names></name><name><surname>Zenklusen</surname><given-names>J. C.</given-names></name><name><surname>Kotliarov</surname><given-names>Y.</given-names></name><name><surname>Sahni</surname><given-names>H.</given-names></name><name><surname>Fine</surname><given-names>H. A.</given-names></name><name><surname>Buetow</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Rembrandt: helping personalized medicine become a reality through integrative translational research.</article-title>
<source>Mol Cancer Res</source>
<volume>7</volume>, <fpage>157</fpage>-<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-08-0435</pub-id><?supplied-pmid 19208739?><pub-id pub-id-type="pmid">19208739</pub-id></mixed-citation></ref><ref id="r60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maekawa</surname><given-names>M.</given-names></name><name><surname>Yamaguchi</surname><given-names>K.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name><name><surname>Shibukawa</surname><given-names>R.</given-names></name><name><surname>Kodanaka</surname><given-names>I.</given-names></name><name><surname>Ichisaka</surname><given-names>T.</given-names></name><name><surname>Kawamura</surname><given-names>Y.</given-names></name><name><surname>Mochizuki</surname><given-names>H.</given-names></name><name><surname>Goshima</surname><given-names>N.</given-names></name><name><surname>Yamanaka</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1.</article-title>
<source>Nature</source>
<volume>474</volume>, <fpage>225</fpage>-<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1038/nature10106</pub-id><?supplied-pmid 21654807?><pub-id pub-id-type="pmid">21654807</pub-id></mixed-citation></ref><ref id="r61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marincevic-Zuniga</surname><given-names>Y.</given-names></name><name><surname>Zachariadis</surname><given-names>V.</given-names></name><name><surname>Cavelier</surname><given-names>L.</given-names></name><name><surname>Castor</surname><given-names>A.</given-names></name><name><surname>Barbany</surname><given-names>G.</given-names></name><name><surname>Forestier</surname><given-names>E.</given-names></name><name><surname>Fogelstrand</surname><given-names>L.</given-names></name><name><surname>Heyman</surname><given-names>M.</given-names></name><name><surname>Abrahamsson</surname><given-names>J.</given-names></name><name><surname>L&#x000f6;nnerholm</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia.</article-title>
<source>Haematologica</source>
<volume>101</volume>, <fpage>e20</fpage>-<lpage>3</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2015.132332</pub-id><?supplied-pmid 26494837?><pub-id pub-id-type="pmid">26494837</pub-id></mixed-citation></ref><ref id="r62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martello</surname><given-names>G.</given-names></name><name><surname>Sugimoto</surname><given-names>T.</given-names></name><name><surname>Diamanti</surname><given-names>E.</given-names></name><name><surname>Joshi</surname><given-names>A.</given-names></name><name><surname>Hannah</surname><given-names>R.</given-names></name><name><surname>Ohtsuka</surname><given-names>S.</given-names></name><name><surname>G&#x000f6;ttgens</surname><given-names>B.</given-names></name><name><surname>Niwa</surname><given-names>H.</given-names></name><name><surname>Smith</surname><given-names>A.</given-names></name></person-group> (<year>2012</year>). <article-title>Esrrb is a pivotal target of the Gsk3/Tcf3 axis regulating embryonic stem cell self-renewal.</article-title>
<source>Cell Stem Cell</source>
<volume>11</volume>, <fpage>491</fpage>-<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1016/j.stem.2012.06.008</pub-id><?supplied-pmid 23040478?><pub-id pub-id-type="pmid">23040478</pub-id></mixed-citation></ref><ref id="r63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsunaga</surname><given-names>K.</given-names></name><name><surname>Araki</surname><given-names>K.</given-names></name><name><surname>Mizusaki</surname><given-names>H.</given-names></name><name><surname>Morohashi</surname><given-names>K.</given-names></name><name><surname>Haruna</surname><given-names>K.</given-names></name><name><surname>Nakagata</surname><given-names>N.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name><name><surname>Yamamura</surname><given-names>K.</given-names></name><name><surname>Abe</surname><given-names>K.</given-names></name></person-group> (<year>2004</year>). <article-title>Loss of PGC-specific expression of the orphan nuclear receptor ERR-beta results in reduction of germ cell number in mouse embryos.</article-title>
<source>Mech Dev</source>
<volume>121</volume>, <fpage>237</fpage>-<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.mod.2004.01.006</pub-id><?supplied-pmid 15003627?><pub-id pub-id-type="pmid">15003627</pub-id></mixed-citation></ref><ref id="r64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagao</surname><given-names>T.</given-names></name><name><surname>Kagawa</surname><given-names>N.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Komada</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Developmental effects of oral exposure to diethylstilbestrol on mouse placenta.</article-title>
<source>J Appl Toxicol</source>
<volume>33</volume>, <fpage>1213</fpage>-<lpage>1221</lpage>.<?supplied-pmid 22733484?><pub-id pub-id-type="pmid">22733484</pub-id></mixed-citation></ref><ref id="r65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordlund</surname><given-names>J.</given-names></name><name><surname>B&#x000e4;cklin</surname><given-names>C. L.</given-names></name><name><surname>Zachariadis</surname><given-names>V.</given-names></name><name><surname>Cavelier</surname><given-names>L.</given-names></name><name><surname>Dahlberg</surname><given-names>J.</given-names></name><name><surname>&#x000d6;fverholm</surname><given-names>I.</given-names></name><name><surname>Barbany</surname><given-names>G.</given-names></name><name><surname>Nordgren</surname><given-names>A.</given-names></name><name><surname>&#x000d6;vern&#x000e4;s</surname><given-names>E.</given-names></name><name><surname>Abrahamsson</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia.</article-title>
<source>Clin Epigenetics</source>
<volume>7</volume>, <fpage>11</fpage>.<?supplied-pmid 25729447?><pub-id pub-id-type="pmid">25729447</pub-id></mixed-citation></ref><ref id="r66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname><given-names>A.</given-names></name><name><surname>Peng</surname><given-names>G. H.</given-names></name><name><surname>Poth</surname><given-names>E. M.</given-names></name><name><surname>Lee</surname><given-names>D. A.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Alexis</surname><given-names>U.</given-names></name><name><surname>de Melo</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Blackshaw</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>The orphan nuclear hormone receptor ERRbeta controls rod photoreceptor survival.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>107</volume>, <fpage>11579</fpage>-<lpage>11584</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1000102107</pub-id><?supplied-pmid 20534447?><pub-id pub-id-type="pmid">20534447</pub-id></mixed-citation></ref><ref id="r67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>Z.</given-names></name><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Wong</surname><given-names>W. H.</given-names></name></person-group> (<year>2009</year>). <article-title>ChIP-Seq of transcription factors predicts absolute and differential gene expression in embryonic stem cells.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>106</volume>, <fpage>21521</fpage>-<lpage>21526</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0904863106</pub-id><?supplied-pmid 19995984?><pub-id pub-id-type="pmid">19995984</pub-id></mixed-citation></ref><ref id="r68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp</surname><given-names>B.</given-names></name><name><surname>Plath</surname><given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Pluripotency re-centered around Esrrb.</article-title>
<source>EMBO J</source>
<volume>31</volume>, <fpage>4255</fpage>-<lpage>4257</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2012.285</pub-id><?supplied-pmid 23064149?><pub-id pub-id-type="pmid">23064149</pub-id></mixed-citation></ref><ref id="r69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S. R.</given-names></name><name><surname>Skafar</surname><given-names>D. F.</given-names></name></person-group> (<year>2015</year>). <article-title>Modulation of nuclear receptor activity by the F domain.</article-title>
<source>Mol Cell Endocrinol</source>
<volume>418</volume>
<issue>Pt 3</issue>, <fpage>298</fpage>-<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2015.07.009</pub-id><?supplied-pmid 26184856?><pub-id pub-id-type="pmid">26184856</pub-id></mixed-citation></ref><ref id="r70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percharde</surname><given-names>M.</given-names></name><name><surname>Lavial</surname><given-names>F.</given-names></name><name><surname>Ng</surname><given-names>J. H.</given-names></name><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Tomaz</surname><given-names>R. A.</given-names></name><name><surname>Martin</surname><given-names>N.</given-names></name><name><surname>Yeo</surname><given-names>J. C.</given-names></name><name><surname>Gil</surname><given-names>J.</given-names></name><name><surname>Prabhakar</surname><given-names>S.</given-names></name><name><surname>Ng</surname><given-names>H. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Ncoa3 functions as an essential Esrrb coactivator to sustain embryonic stem cell self-renewal and reprogramming.</article-title>
<source>Genes Dev</source>
<volume>26</volume>, <fpage>2286</fpage>-<lpage>2298</lpage>. <pub-id pub-id-type="doi">10.1101/gad.195545.112</pub-id><?supplied-pmid 23019124?><pub-id pub-id-type="pmid">23019124</pub-id></mixed-citation></ref><ref id="r71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersson</surname><given-names>K.</given-names></name><name><surname>Svensson</surname><given-names>K.</given-names></name><name><surname>Mattsson</surname><given-names>R.</given-names></name><name><surname>Carlsson</surname><given-names>B.</given-names></name><name><surname>Ohlsson</surname><given-names>R.</given-names></name><name><surname>Berkenstam</surname><given-names>A.</given-names></name></person-group> (<year>1996</year>). <article-title>Expression of a novel member of estrogen response element-binding nuclear receptors is restricted to the early stages of chorion formation during mouse embryogenesis.</article-title>
<source>Mech Dev</source>
<volume>54</volume>, <fpage>211</fpage>-<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1016/0925-4773(95)00479-3</pub-id><?supplied-pmid 8652414?><pub-id pub-id-type="pmid">8652414</pub-id></mixed-citation></ref><ref id="r72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prados</surname><given-names>M. D.</given-names></name><name><surname>Byron</surname><given-names>S. A.</given-names></name><name><surname>Tran</surname><given-names>N. L.</given-names></name><name><surname>Phillips</surname><given-names>J. J.</given-names></name><name><surname>Molinaro</surname><given-names>A. M.</given-names></name><name><surname>Ligon</surname><given-names>K. L.</given-names></name><name><surname>Wen</surname><given-names>P. Y.</given-names></name><name><surname>Kuhn</surname><given-names>J. G.</given-names></name><name><surname>Mellinghoff</surname><given-names>I. K.</given-names></name><name><surname>de Groot</surname><given-names>J. F.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Toward precision medicine in glioblastoma: the promise and the challenges.</article-title>
<source>Neuro Oncol</source>. <volume>17</volume>, <fpage>1051</fpage>-<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1093/neuonc/nov031</pub-id><?supplied-pmid 25934816?><pub-id pub-id-type="pmid">25934816</pub-id></mixed-citation></ref><ref id="r73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Real</surname><given-names>M. A.</given-names></name><name><surname>Heredia</surname><given-names>R.</given-names></name><name><surname>D&#x000e1;vila</surname><given-names>J. C.</given-names></name><name><surname>Guirado</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Efferent retinal projections visualized by immunohistochemical detection of the estrogen-related receptor beta in the postnatal and adult mouse brain.</article-title>
<source>Neurosci Lett</source>
<volume>438</volume>, <fpage>48</fpage>-<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2008.04.044</pub-id><?supplied-pmid 18472334?><pub-id pub-id-type="pmid">18472334</pub-id></mixed-citation></ref><ref id="r74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>D.</given-names></name><name><surname>Nakaso</surname><given-names>K.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Parkin degrades estrogen-related receptors to limit the expression of monoamine oxidases.</article-title>
<source>Hum Mol Genet</source>
<volume>20</volume>, <fpage>1074</fpage>-<lpage>1083</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq550</pub-id><?supplied-pmid 21177257?><pub-id pub-id-type="pmid">21177257</pub-id></mixed-citation></ref><ref id="r75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>B.</given-names></name><name><surname>Haupt</surname><given-names>L. M.</given-names></name><name><surname>Griffiths</surname><given-names>L. R.</given-names></name></person-group> (<year>2013</year>). <article-title>Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity.</article-title>
<source>Curr Genomics</source>
<volume>14</volume>, <fpage>182</fpage>-<lpage>194</lpage>. <pub-id pub-id-type="doi">10.2174/1389202911314030004</pub-id><?supplied-pmid 24179441?><pub-id pub-id-type="pmid">24179441</pub-id></mixed-citation></ref><ref id="r76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>J. N.</given-names></name><name><surname>Adejokun</surname><given-names>F.</given-names></name></person-group> (<year>1980</year>). <article-title>Placental changes due to administration of diethylstilbestrol (DES).</article-title>
<source>Virchows Arch B Cell Pathol Incl Mol Pathol</source>
<volume>34</volume>, <fpage>261</fpage>-<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1007/BF02892423</pub-id><?supplied-pmid 6108645?><pub-id pub-id-type="pmid">6108645</pub-id></mixed-citation></ref><ref id="r77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sem</surname><given-names>D. S.</given-names></name><name><surname>Casimiro</surname><given-names>D. R.</given-names></name><name><surname>Kliewer</surname><given-names>S. A.</given-names></name><name><surname>Provencal</surname><given-names>J.</given-names></name><name><surname>Evans</surname><given-names>R. M.</given-names></name><name><surname>Wright</surname><given-names>P. E.</given-names></name></person-group> (<year>1997</year>). <article-title>NMR spectroscopic studies of the DNA-binding domain of the monomer-binding nuclear orphan receptor, human estrogen related receptor-2. The carboxyl-terminal extension to the zinc-finger region is unstructured in the free form of the protein.</article-title>
<source>J Biol Chem</source>
<volume>272</volume>, <fpage>18038</fpage>-<lpage>18043</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.29.18038</pub-id><?supplied-pmid 9218433?><pub-id pub-id-type="pmid">9218433</pub-id></mixed-citation></ref><ref id="r78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>D.</given-names></name><name><surname>Bhargava</surname><given-names>D. K.</given-names></name><name><surname>Dixit</surname><given-names>A.</given-names></name><name><surname>Sahoo</surname><given-names>B. S.</given-names></name><name><surname>Biswas</surname><given-names>S.</given-names></name><name><surname>Biswas</surname><given-names>G.</given-names></name><name><surname>Mishra</surname><given-names>S. K.</given-names></name></person-group> (<year>2014</year>). <article-title>ERR&#x003b2; signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells.</article-title>
<source>Br J Cancer</source>
<volume>110</volume>, <fpage>2144</fpage>-<lpage>2158</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2014.53</pub-id><?supplied-pmid 24667650?><pub-id pub-id-type="pmid">24667650</pub-id></mixed-citation></ref><ref id="r79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>D.</given-names></name><name><surname>Blackshaw</surname><given-names>S.</given-names></name><name><surname>Cepko</surname><given-names>C. L.</given-names></name><name><surname>Dryja</surname><given-names>T. P.</given-names></name></person-group> (<year>2002</year>). <article-title>Profile of the genes expressed in the human peripheral retina, macula, and retinal pigment epithelium determined through serial analysis of gene expression (SAGE).</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>99</volume>, <fpage>315</fpage>-<lpage>320</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.012582799</pub-id><?supplied-pmid 11756676?><pub-id pub-id-type="pmid">11756676</pub-id></mixed-citation></ref><ref id="r80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skafar</surname><given-names>D. F.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>The multifunctional estrogen receptor-alpha F domain.</article-title>
<source>Endocrine</source>
<volume>33</volume>, <fpage>1</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s12020-008-9054-1</pub-id><?supplied-pmid 18363044?><pub-id pub-id-type="pmid">18363044</pub-id></mixed-citation></ref><ref id="r81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sladek</surname><given-names>R.</given-names></name><name><surname>Beatty</surname><given-names>B.</given-names></name><name><surname>Squire</surname><given-names>J.</given-names></name><name><surname>Copeland</surname><given-names>N. G.</given-names></name><name><surname>Gilbert</surname><given-names>D. J.</given-names></name><name><surname>Jenkins</surname><given-names>N. A.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name></person-group> (<year>1997</year>). <article-title>Chromosomal mapping of the human and murine orphan receptors ERRalpha (ESRRA) and ERRbeta (ESRRB) and identification of a novel human ERRalpha-related pseudogene.</article-title>
<source>Genomics</source>
<volume>45</volume>, <fpage>320</fpage>-<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1006/geno.1997.4939</pub-id><?supplied-pmid 9344655?><pub-id pub-id-type="pmid">9344655</pub-id></mixed-citation></ref><ref id="r82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suetsugi</surname><given-names>M.</given-names></name><name><surname>Su</surname><given-names>L.</given-names></name><name><surname>Karlsberg</surname><given-names>K.</given-names></name><name><surname>Yuan</surname><given-names>Y. C.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name></person-group> (<year>2003</year>). <article-title>Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors.</article-title>
<source>Mol Cancer Res</source>
<volume>1</volume>, <fpage>981</fpage>-<lpage>991</lpage>.<?supplied-pmid 14638870?><pub-id pub-id-type="pmid">14638870</pub-id></mixed-citation></ref><ref id="r83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Kasahara</surname><given-names>M.</given-names></name><name><surname>Yoshioka</surname><given-names>H.</given-names></name><name><surname>Morohashi</surname><given-names>K.</given-names></name><name><surname>Umesono</surname><given-names>K.</given-names></name></person-group> (<year>2003</year>). <article-title>LXXLL-related motifs in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 and LRH-1.</article-title>
<source>Mol Cell Biol</source>
<volume>23</volume>, <fpage>238</fpage>-<lpage>249</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.23.1.238-249.2003</pub-id><?supplied-pmid 12482977?><pub-id pub-id-type="pmid">12482977</pub-id></mixed-citation></ref><ref id="r84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takacs</surname><given-names>M.</given-names></name><name><surname>Petoukhov</surname><given-names>M. V.</given-names></name><name><surname>Atkinson</surname><given-names>R. A.</given-names></name><name><surname>Roblin</surname><given-names>P.</given-names></name><name><surname>Ogi</surname><given-names>F. X.</given-names></name><name><surname>Demeler</surname><given-names>B.</given-names></name><name><surname>Potier</surname><given-names>N.</given-names></name><name><surname>Chebaro</surname><given-names>Y.</given-names></name><name><surname>Dejaegere</surname><given-names>A.</given-names></name><name><surname>Svergun</surname><given-names>D. I.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>The asymmetric binding of PGC-1&#x003b1; to the ERR&#x003b1; and ERR&#x003b3; nuclear receptor homodimers involves a similar recognition mechanism.</article-title>
<source>PLoS One</source>
<volume>8</volume>, <fpage>e67810</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0067810</pub-id><?supplied-pmid 23874451?><pub-id pub-id-type="pmid">23874451</pub-id></mixed-citation></ref><ref id="r85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayanagi</surname><given-names>S.</given-names></name><name><surname>Tokunaga</surname><given-names>T.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Okada</surname><given-names>H.</given-names></name><name><surname>Matsushima</surname><given-names>A.</given-names></name><name><surname>Shimohigashi</surname><given-names>Y.</given-names></name></person-group> (<year>2006</year>). <article-title>Endocrine disruptor bisphenol A strongly binds to human estrogen-related receptor gamma (ERRgamma) with high constitutive activity.</article-title>
<source>Toxicol. Lett.</source>
<volume>167</volume>, <fpage>95</fpage>-<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.toxlet.2006.08.012</pub-id><?supplied-pmid 17049190?><pub-id pub-id-type="pmid">17049190</pub-id></mixed-citation></ref><ref id="r86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanida</surname><given-names>T.</given-names></name><name><surname>Matsuda</surname><given-names>K. I.</given-names></name><name><surname>Yamada</surname><given-names>S.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Kawata</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Estrogen-Related Receptor &#x003b2; Reduces the Subnuclear Mobility of Estrogen Receptor &#x003b1; and Suppresses Estrogen-Dependent Cellular Function.</article-title>
<source>J Biol Chem</source>. <volume>290</volume>, <fpage>12332</fpage>-<lpage>12345</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M114.619098</pub-id><?supplied-pmid 25805499?><pub-id pub-id-type="pmid">25805499</pub-id></mixed-citation></ref><ref id="r87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarrant</surname><given-names>A. M.</given-names></name><name><surname>Greytak</surname><given-names>S. R.</given-names></name><name><surname>Callard</surname><given-names>G. V.</given-names></name><name><surname>Hahn</surname><given-names>M. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Estrogen receptor-related receptors in the killifish Fundulus heteroclitus: diversity, expression, and estrogen responsiveness.</article-title>
<source>J Mol Endocrinol</source>
<volume>37</volume>, <fpage>105</fpage>-<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1677/jme.1.01976</pub-id><?supplied-pmid 16901928?><pub-id pub-id-type="pmid">16901928</pub-id></mixed-citation></ref><ref id="r88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapp</surname><given-names>T.</given-names></name><name><surname>Holsboer</surname><given-names>F.</given-names></name></person-group> (<year>1996</year>). <article-title>Nuclear orphan receptor as a repressor of glucocorticoid receptor transcriptional activity.</article-title>
<source>J Biol Chem</source>
<volume>271</volume>, <fpage>9879</fpage>-<lpage>9882</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.17.9879</pub-id><?supplied-pmid 8626619?><pub-id pub-id-type="pmid">8626619</pub-id></mixed-citation></ref><ref id="r89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>G. B.</given-names></name><name><surname>Bergeron</surname><given-names>D.</given-names></name><name><surname>Giguere</surname><given-names>V.</given-names></name></person-group> (<year>2001</year><comment>a</comment>). <article-title>4-Hydroxytamoxifen is an isoform-specific inhibitor of orphan estrogen-receptor-related (ERR) nuclear receptors beta and gamma.</article-title>
<source>Endocrinology</source>
<volume>142</volume>, <fpage>4572</fpage>-<lpage>4575</lpage>.<?supplied-pmid 11564725?><pub-id pub-id-type="pmid">11564725</pub-id></mixed-citation></ref><ref id="r90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>G. B.</given-names></name><name><surname>Kunath</surname><given-names>T.</given-names></name><name><surname>Bergeron</surname><given-names>D.</given-names></name><name><surname>Lapointe</surname><given-names>L.</given-names></name><name><surname>Champigny</surname><given-names>C.</given-names></name><name><surname>Bader</surname><given-names>J. A.</given-names></name><name><surname>Rossant</surname><given-names>J.</given-names></name><name><surname>Gigu&#x000e8;re</surname><given-names>V.</given-names></name></person-group> (<year>2001</year><comment>b</comment>). <article-title>Diethylstilbestrol regulates trophoblast stem cell differentiation as a ligand of orphan nuclear receptor ERR beta.</article-title>
<source>Genes Dev</source>
<volume>15</volume>, <fpage>833</fpage>-<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1101/gad.873401</pub-id><?supplied-pmid 11297507?><pub-id pub-id-type="pmid">11297507</pub-id></mixed-citation></ref><ref id="r91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twigger</surname><given-names>A. J.</given-names></name><name><surname>Hepworth</surname><given-names>A. R.</given-names></name><name><surname>Lai</surname><given-names>C. T.</given-names></name><name><surname>Chetwynd</surname><given-names>E.</given-names></name><name><surname>Stuebe</surname><given-names>A. M.</given-names></name><name><surname>Blancafort</surname><given-names>P.</given-names></name><name><surname>Hartmann</surname><given-names>P. E.</given-names></name><name><surname>Geddes</surname><given-names>D. T.</given-names></name><name><surname>Kakulas</surname><given-names>F.</given-names></name></person-group> (<year>2015</year>). <article-title>Gene expression in breastmilk cells is associated with maternal and infant characteristics.</article-title>
<source>Sci Rep</source>
<volume>5</volume>, <fpage>12933</fpage>. <pub-id pub-id-type="doi">10.1038/srep12933</pub-id><?supplied-pmid 26255679?><pub-id pub-id-type="pmid">26255679</pub-id></mixed-citation></ref><ref id="r92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>G. C.</given-names></name><name><surname>Murata</surname><given-names>T.</given-names></name><name><surname>Hirose</surname><given-names>S.</given-names></name></person-group> (<year>1992</year>). <article-title>A novel DNA-binding motif abuts the zinc finger domain of insect nuclear hormone receptor FTZ-F1 and mouse embryonal long terminal repeat-binding protein.</article-title>
<source>Mol Cell Biol</source>
<volume>12</volume>, <fpage>5667</fpage>-<lpage>5672</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.12.12.5667</pub-id><?supplied-pmid 1448096?><pub-id pub-id-type="pmid">1448096</pub-id></mixed-citation></ref><ref id="r93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uranishi</surname><given-names>K.</given-names></name><name><surname>Akagi</surname><given-names>T.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Koide</surname><given-names>H.</given-names></name><name><surname>Yokota</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Dax1 associates with Esrrb and regulates its function in embryonic stem cells.</article-title>
<source>Mol Cell Biol</source>
<volume>33</volume>, <fpage>2056</fpage>-<lpage>2066</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.01520-12</pub-id><?supplied-pmid 23508100?><pub-id pub-id-type="pmid">23508100</pub-id></mixed-citation></ref><ref id="r94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Laan</surname><given-names>S.</given-names></name><name><surname>Golfetto</surname><given-names>E.</given-names></name><name><surname>Vanacker</surname><given-names>J. M.</given-names></name><name><surname>Maiorano</surname><given-names>D.</given-names></name></person-group> (<year>2014</year>). <article-title>Cell cycle-dependent expression of Dub3, Nanog and the p160 family of nuclear receptor coactivators (NCoAs) in mouse embryonic stem cells.</article-title>
<source>PLoS One</source>
<volume>9</volume>, <fpage>e93663</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0093663</pub-id><?supplied-pmid 24695638?><pub-id pub-id-type="pmid">24695638</pub-id></mixed-citation></ref><ref id="r95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Laan</surname><given-names>S.</given-names></name><name><surname>Tsanov</surname><given-names>N.</given-names></name><name><surname>Crozet</surname><given-names>C.</given-names></name><name><surname>Maiorano</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>High Dub3 expression in mouse ESCs couples the G1/S checkpoint to pluripotency.</article-title>
<source>Mol Cell</source>
<volume>52</volume>, <fpage>366</fpage>-<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2013.10.003</pub-id><?supplied-pmid 24207026?><pub-id pub-id-type="pmid">24207026</pub-id></mixed-citation></ref><ref id="r96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanacker</surname><given-names>J. M.</given-names></name><name><surname>Bonnelye</surname><given-names>E.</given-names></name><name><surname>Chopin-Delannoy</surname><given-names>S.</given-names></name><name><surname>Delmarre</surname><given-names>C.</given-names></name><name><surname>Cavailles</surname><given-names>V.</given-names></name><name><surname>Laudet</surname><given-names>V.</given-names></name></person-group> (<year>1999</year>). <article-title>Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha).</article-title>
<source>Molecular Endocrinology</source>
<volume>13</volume>, <fpage>764</fpage>-<lpage>773</lpage>.<?supplied-pmid 10319326?><pub-id pub-id-type="pmid">10319326</pub-id></mixed-citation></ref><ref id="r97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanacker</surname><given-names>J. M.</given-names></name><name><surname>Maiorano</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Checking the cycle by ERR&#x003b2; splice variants.</article-title>
<source>Cell Cycle</source>
<volume>14</volume>, <fpage>1492</fpage>-<lpage>1493</lpage>. <pub-id pub-id-type="doi">10.1080/15384101.2015.1024588</pub-id><?supplied-pmid 25789879?><pub-id pub-id-type="pmid">25789879</pub-id></mixed-citation></ref><ref id="r98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>). <article-title>Kaempferol is an estrogen-related receptor alpha and gamma inverse agonist.</article-title>
<source>FEBS Lett</source>
<volume>583</volume>, <fpage>643</fpage>-<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2009.01.030</pub-id><?supplied-pmid 19171140?><pub-id pub-id-type="pmid">19171140</pub-id></mixed-citation></ref><ref id="r99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zuercher</surname><given-names>W. J.</given-names></name><name><surname>Consler</surname><given-names>T. G.</given-names></name><name><surname>Lambert</surname><given-names>M. H.</given-names></name><name><surname>Miller</surname><given-names>A. B.</given-names></name><name><surname>Orband-Miller</surname><given-names>L. A.</given-names></name><name><surname>McKee</surname><given-names>D. D.</given-names></name><name><surname>Willson</surname><given-names>T. M.</given-names></name><name><surname>Nolte</surname><given-names>R. T.</given-names></name></person-group> (<year>2006</year>). <article-title>X-ray crystal structures of the estrogen-related receptor-gamma ligand binding domain in three functional states reveal the molecular basis of small molecule regulation.</article-title>
<source>J Biol Chem</source>
<volume>281</volume>, <fpage>37773</fpage>-<lpage>37781</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M608410200</pub-id><?supplied-pmid 16990259?><pub-id pub-id-type="pmid">16990259</pub-id></mixed-citation></ref><ref id="r100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S. C.</given-names></name><name><surname>Myers</surname><given-names>S.</given-names></name><name><surname>Dooms</surname><given-names>C.</given-names></name><name><surname>Capon</surname><given-names>R.</given-names></name><name><surname>Muscat</surname><given-names>G. E.</given-names></name></person-group> (<year>2010</year><comment>a</comment>). <article-title>An ERRbeta/gamma agonist modulates GRalpha expression, and glucocorticoid responsive gene expression in skeletal muscle cells.</article-title>
<source>Mol Cell Endocrinol</source>
<volume>315</volume>, <fpage>146</fpage>-<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2009.07.012</pub-id><?supplied-pmid 19631715?><pub-id pub-id-type="pmid">19631715</pub-id></mixed-citation></ref><ref id="r101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Arvanites</surname><given-names>A. C.</given-names></name><name><surname>Davidow</surname><given-names>L.</given-names></name><name><surname>Blanchard</surname><given-names>J.</given-names></name><name><surname>Lam</surname><given-names>K.</given-names></name><name><surname>Yoo</surname><given-names>J. W.</given-names></name><name><surname>Coy</surname><given-names>S.</given-names></name><name><surname>Rubin</surname><given-names>L. L.</given-names></name><name><surname>McMahon</surname><given-names>A. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation.</article-title>
<source>ACS Chem Biol</source>
<volume>7</volume>, <fpage>1040</fpage>-<lpage>1048</lpage>. <pub-id pub-id-type="doi">10.1021/cb300028a</pub-id><?supplied-pmid 22554036?><pub-id pub-id-type="pmid">22554036</pub-id></mixed-citation></ref><ref id="r102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Wong</surname><given-names>C. W.</given-names></name></person-group> (<year>2010</year><comment>b</comment>). <article-title>Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist.</article-title>
<source>Biochem Pharmacol</source>
<volume>80</volume>, <fpage>80</fpage>-<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2010.03.013</pub-id><?supplied-pmid 20298676?><pub-id pub-id-type="pmid">20298676</pub-id></mixed-citation></ref><ref id="r103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>M. L.</given-names></name><name><surname>Hsin</surname><given-names>H. Y.</given-names></name><name><surname>Kalay</surname><given-names>E.</given-names></name></person-group>, Bro&#x0017d;kov&#x000e1;, D. S., Shimizu, T., Bayram, M., Deeley, K., K&#x000fc;chler, E. C., Forella, J., Ruff, T. D., <italic>et al</italic><italic>.</italic> (<year>2014</year>). <article-title>Role of estrogen related receptor beta (ESRRB) in DFN35B hearing impairment and dental decay.</article-title>
<source>BMC Med Genet</source>
<volume>15</volume>, <fpage>81</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2350-15-81</pub-id><?supplied-pmid 25023176?><pub-id pub-id-type="pmid">25023176</pub-id></mixed-citation></ref><ref id="r104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C. C.</given-names></name><name><surname>Lin</surname><given-names>Y. H.</given-names></name><name><surname>Liu</surname><given-names>T. C.</given-names></name><name><surname>Lin</surname><given-names>K. N.</given-names></name><name><surname>Yang</surname><given-names>W. S.</given-names></name><name><surname>Hsu</surname><given-names>C. J.</given-names></name><name><surname>Chen</surname><given-names>P. L.</given-names></name><name><surname>Wu</surname><given-names>C. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Identifying Children With Poor Cochlear Implantation Outcomes Using Massively Parallel Sequencing.</article-title>
<source>Medicine (Baltimore)</source>
<volume>94</volume>, <fpage>e1073</fpage>. <pub-id pub-id-type="doi">10.1097/MD.0000000000001073</pub-id><?supplied-pmid 26166082?><pub-id pub-id-type="pmid">26166082</pub-id></mixed-citation></ref><ref id="r105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2012</year>). <article-title>Role of nuclear receptor coactivator 3 (Ncoa3) in pluripotency maintenance.</article-title>
<source>J Biol Chem</source>
<volume>287</volume>, <fpage>38295</fpage>-<lpage>38304</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.373092</pub-id><?supplied-pmid 22977234?><pub-id pub-id-type="pmid">22977234</pub-id></mixed-citation></ref><ref id="r106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>C. Q.</given-names></name><name><surname>Jeong</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>Bookout</surname><given-names>A. L.</given-names></name><name><surname>Garcia-Barrio</surname><given-names>M. T.</given-names></name><name><surname>Sun</surname><given-names>T.</given-names></name><name><surname>Kim</surname><given-names>B. H.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><name><surname>Root</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>Expression profiling of nuclear receptors in human and mouse embryonic stem cells.</article-title>
<source>Mol Endocrinol</source>
<volume>23</volume>, <fpage>724</fpage>-<lpage>733</lpage>. <pub-id pub-id-type="doi">10.1210/me.2008-0465</pub-id><?supplied-pmid 19196830?><pub-id pub-id-type="pmid">19196830</pub-id></mixed-citation></ref><ref id="r107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Hong</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>N. N.</given-names></name><name><surname>Lin</surname><given-names>R. J.</given-names></name><name><surname>Simon</surname><given-names>C. M.</given-names></name><name><surname>Stallcup</surname><given-names>M. R.</given-names></name><name><surname>Evans</surname><given-names>R. M.</given-names></name></person-group> (<year>1999</year>). <article-title>Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2.</article-title>
<source>Mol Endocrinol</source>
<volume>13</volume>, <fpage>2151</fpage>-<lpage>2162</lpage>. <pub-id pub-id-type="doi">10.1210/mend.13.12.0381</pub-id><?supplied-pmid 10598588?><pub-id pub-id-type="pmid">10598588</pub-id></mixed-citation></ref><ref id="r108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Sawada</surname><given-names>M.</given-names></name><name><surname>Kuroboshi</surname><given-names>H.</given-names></name><name><surname>Tatsumi</surname><given-names>H.</given-names></name><name><surname>Yoshioka</surname><given-names>T.</given-names></name><name><surname>Matsushima</surname><given-names>H.</given-names></name><name><surname>Iwasaku</surname><given-names>K.</given-names></name><name><surname>Kitawaki</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>). <article-title>Estrogen-related receptor-&#x003b3; regulates estrogen receptor-&#x003b1; responsiveness in uterine endometrial cancer.</article-title>
<source>Int J Gynecol Cancer</source>
<volume>22</volume>, <fpage>1509</fpage>-<lpage>1516</lpage>.<?supplied-pmid 23051957?><pub-id pub-id-type="pmid">23051957</pub-id></mixed-citation></ref><ref id="r109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Hang</surname><given-names>J.</given-names></name><name><surname>Wan</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Wong</surname><given-names>C. C.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Structure of a yeast spliceosome at 3.6-angstrom resolution.</article-title>
<source>Science</source>
<volume>349</volume>, <fpage>1182</fpage>-<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac7629</pub-id><?supplied-pmid 26292707?><pub-id pub-id-type="pmid">26292707</pub-id></mixed-citation></ref><ref id="r110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F.</given-names></name><name><surname>Du</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Xiao</surname><given-names>Q.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2015</year>). <article-title>Characterization and functional analysis of porcine estrogen-related receptors and their alternative splicing variants.</article-title>
<source>J Anim Sci</source>
<volume>93</volume>, <fpage>4258</fpage>-<lpage>4266</lpage>. <pub-id pub-id-type="doi">10.2527/jas.2015-9188</pub-id><?supplied-pmid 26440325?><pub-id pub-id-type="pmid">26440325</pub-id></mixed-citation></ref><ref id="r111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D. D.</given-names></name><name><surname>Forman</surname><given-names>B. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma 1.</article-title>
<source>Bioorg. Med. Chem. Lett.</source>
<volume>15</volume>, <fpage>1311</fpage>-<lpage>1313</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.01.025</pub-id><?supplied-pmid 15713377?><pub-id pub-id-type="pmid">15713377</pub-id></mixed-citation></ref><ref id="r112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>Y. C.</given-names></name><name><surname>Wang</surname><given-names>X. H.</given-names></name><name><surname>Ling</surname><given-names>M. T.</given-names></name><name><surname>Ng</surname><given-names>C. F.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chan</surname><given-names>F. L.</given-names></name></person-group> (<year>2008</year>). <article-title>Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer.</article-title>
<source>Oncogene</source>
<volume>27</volume>, <fpage>3313</fpage>-<lpage>3328</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210986</pub-id><?supplied-pmid 18071305?><pub-id pub-id-type="pmid">18071305</pub-id></mixed-citation></ref><ref id="r113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q.</given-names></name><name><surname>Chipperfield</surname><given-names>H.</given-names></name><name><surname>Melton</surname><given-names>D. A.</given-names></name><name><surname>Wong</surname><given-names>W. H.</given-names></name></person-group> (<year>2007</year><comment>a</comment>). <article-title>A gene regulatory network in mouse embryonic stem cells.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<volume>104</volume>, <fpage>16438</fpage>-<lpage>16443</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0701014104</pub-id><?supplied-pmid 17940043?><pub-id pub-id-type="pmid">17940043</pub-id></mixed-citation></ref><ref id="r114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>J. H.</given-names></name><name><surname>Hyder</surname><given-names>S. M.</given-names></name><name><surname>Antoniou</surname><given-names>E.</given-names></name><name><surname>Lubahn</surname><given-names>D. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Identification and characterization of two novel splicing isoforms of human estrogen-related receptor beta.</article-title>
<source>J Clin Endocrinol Metab</source>
<volume>91</volume>, <fpage>569</fpage>-<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2004-1957</pub-id><?supplied-pmid 16332939?><pub-id pub-id-type="pmid">16332939</pub-id></mixed-citation></ref><ref id="r115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Lo</surname><given-names>S. C.</given-names></name><name><surname>Liu</surname><given-names>J. H.</given-names></name><name><surname>Hannink</surname><given-names>M.</given-names></name><name><surname>Lubahn</surname><given-names>D. B.</given-names></name></person-group> (<year>2007</year><comment>b</comment>). <article-title>ERRbeta: a potent inhibitor of Nrf2 transcriptional activity.</article-title>
<source>Mol Cell Endocrinol</source>
<volume>278</volume>, <fpage>52</fpage>-<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2007.08.011</pub-id><?supplied-pmid 17920186?><pub-id pub-id-type="pmid">17920186</pub-id></mixed-citation></ref><ref id="r116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuercher</surname><given-names>W. J.</given-names></name><name><surname>Gaillard</surname><given-names>S.</given-names></name><name><surname>Orband-Miller</surname><given-names>L. A.</given-names></name><name><surname>Chao</surname><given-names>E. Y.</given-names></name><name><surname>Shearer</surname><given-names>B. G.</given-names></name><name><surname>Jones</surname><given-names>D. G.</given-names></name><name><surname>Miller</surname><given-names>A. B.</given-names></name><name><surname>Collins</surname><given-names>J. L.</given-names></name><name><surname>McDonnell</surname><given-names>D. P.</given-names></name><name><surname>Willson</surname><given-names>T. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma 2 7337.</article-title>
<source>J. Med. Chem.</source>
<volume>48</volume>, <fpage>3107</fpage>-<lpage>3109</lpage>. <pub-id pub-id-type="doi">10.1021/jm050161j</pub-id><?supplied-pmid 15857113?><pub-id pub-id-type="pmid">15857113</pub-id></mixed-citation></ref></ref-list></back></article>